slides for covid 19 presentation

Unsupported browser

This site was designed for modern browsers and tested with Internet Explorer version 10 and later.

It may not look or work correctly on your browser.

15 Best Free Covid Coronavirus & Virus PowerPoint PPT Templates 2024

Whether you need to make a Covid-related or any other medical presentation, one thing is certain. It’s much faster to start with a coronavirus PowerPoint template than trying to do it from scratch. 

Luckily, there are plenty of free and premium Covid and virus-themed PPT templates available online that you can use as a starting point. 

The Best Source for COVID Coronavirus and Virus PowerPoint Templates (With Unlimited Use)

Envato Elements is the best place to find premium coronavirus, Covid, and virus PowerPoint templates with professional designs. Envato Elements is a subscription-based marketplace. It gives you access to thousands of creative assets — for a single monthly fee:

• premium PowerPoint templates for all your presentation needs
• stock photos and royalty-free music that you can use in your presentations
• fonts, icons, and more to customize your presentation

Explore Virus PowerPoint Templates Now

Envato Elements gives you the best bang for your buck if you need PowerPoint templates and other design assets regularly. Unlike our premium templates, free PowerPoint designs often lack features and customization options.

Top 5 Premium Covid and Coronavirus PowerPoint Templates From Envato Elements for 2024

Before we show you the best free PowerPoint templates with virus themes, here are the top premium coronavirus PowerPoint templates from Envato Elements:

1. Delta Corona Virus PowerPoint Template

First, we've got the Delta Corona Virus PowerPoint template with a modern and clean design. This Covid slides template features 80+ slides. They've got all the necessary content ideas for you to create an engaging presentation.

The template also comes with handmade infographic elements. It was designed in HD resolution and comes in dark and light versions.

2. Covid-19 Virus - Medical PowerPoint Template

The Covid-19 is a medical PowerPoint template with more than 70 unique and modern slides. This Covid presentation template has a gorgeous duotone color scheme, but you can easily customize it to match your brand. You’ll also find unique mockup devices, image placeholders, infographic elements, and more. The template comes in widescreen resolution. 

3. Covirus - Disease & Virus PowerPoint Template

Here’s a unique and trendy Covid and virus PowerPoint template that'll make creating your presentation a breeze. The template comes with 33 unique slides. You can customize colors, fonts, and even the slide layout to create the perfect presentation. You’ll also find image and media placeholders, vector-based icons, and mockup devices. 

4. Secure Virus 19 Medical PowerPoint Template

This coronavirus PPT has twenty-five unique slides. It can help you deliver a comprehensive presentation. Finding the right color scheme for your business won't be a problem. Included are over ninety color schemes that are fully customizable.

You'll find much-needed infographics, vectors, and charts as well. Download this complete Covid PowerPoint template.

5. Covid Virus - Medical PowerPoint Template

This Covid presentation template gives you the power to create an eye-catching presentation. Included are forty-six slides that feature modern designs. Many graphics are included to help you deliver a compelling presentation to your audience. Free web fonts are included, and you can drag and drop in images of your choice to any slide.

The premium templates mentioned are some of the highest quality available. If you're on a budget, you may not be able to afford the premium templates. In this next section, we'll go over the top free PowerPoint templates virus. 

15 Top Free Covid Coronavirus & Virus PowerPoint Templates to Download

Before looking for a free Covid PowerPoint template on the web, check Envato's free offerings first. Try out various premium template files (not always PowerPoint files) at no cost to you.

Here's the deal: 

With that in mind, here are the best free coronavirus and virus PowerPoint templates that you can find and download online for your presentation: 

1. Free Social Distance PowerPoint Template

With the help of this coronavirus PowerPoint template for free, you’ll have no problem explaining social distancing rules. The Covid PowerPoint template includes four pre-designed slides.

2. Medicine Health Care PowerPoint Templates

Try this medicine and healthcare PowerPoint template if you’re looking for a modern template. Use it to present all the necessary information about Coronavirus or any other medical emergency.

3. Medical Laboratory PowerPoint Templates

Here’s a free template virus that would be perfect for any type of virus research presentation. The template comes with individual slides as well as section covers. It includes 25 slides.

4. Coronavirus Pandemic PowerPoint Templates

Share important findings and information about Coronavirus or any other virus with this modern template. It comes with three master slides that you can customize.

5. Covid-19 Coronavirus PowerPoint Templates  

This free Covid PowerPoint template has a dark green background with virus icons. Use it to quickly create a presentation. The template comes with three master slides designed in several resolutions.

6. Infection PowerPoint Templates

Use this fun infection PowerPoint template to create a presentation about virus research or to provide more information about a specific virus. The Coronavirus PPT includes three master slides that you can duplicate to create your presentation.

7. Free COVID-19 Vaccine PowerPoint Template

With the help of this free PowerPoint template with a virus theme, you can easily share all the information people need to know about Covid-19 vaccines. The Covid vaccine theme PowerPoint comes with four slides.

8. Free COVID-19 Presentation Template

Use this Covid presentation template to create a presentation that shares information about the virus and how to fight it. The template has four master slides that you can copy as many times as you need.

9. Free Covid PowerPoint Template

Here’s a minimal and simple COVID PowerPoint template. It features an image that shows the virus spreading all over the world. It also contains four master Covid PowerPoint slides that you can copy for your presentation. 

10. Free COVID PowerPoint Background

Consider this free COVID PowerPoint background for your presentation. It features an image of a word game spelling out coronavirus, pandemic, and virus. 

11. Medical Illustrated. Free PowerPoint Template & Google Slides Theme

Here’s another minimal and clean PowerPoint template. Use it for any type of medical presentation. The Covid presentation template comes with 25 slides.

12. Blue Medical. Free PowerPoint Template & Google Slides Theme

The blue color in this medical and virus PowerPoint template conveys professionalism. It comes with 25 covid PowerPoint slides.

13. Medical Virus. Free PowerPoint Template & Google Slides Theme

This coronavirus PowerPoint template for free can be used for sharing information about the virus and how to prevent the spread. The template comes with 25 slides that you can duplicate, re-order, and delete as you see fit.

14. Free COVID-19 Health System Capacity Curve PowerPoint

Use this free Covid-19 PowerPoint template to showcase the virus's effect on the health system capacity. The template includes several different slide variations.

15. Coronavirus PowerPoint Template

Use this coronavirus PowerPoint template for free to create informative presentations about coronavirus measures, treatments, and protection. It comes with several slides, including section cover and agenda slides. 

How to Make a Coronavirus Presentation in PowerPoint

1. Choose the Right Slides

Not all the slides in the template will work for your presentation. Go through each slide and pick the ones that pertain to your presentation. For the slides, you don't want to use, left-click the slide and choose Delete Slide .

2. Add In Your Content

Now it's time to add in your presentation's content. Have a document open with all the text you want to use for each slide. Then copy and paste the text to each slide.

Each slide has text placeholders. Double-click the placeholder text and select all the text. You can then paste in your text.

3. Add In Your Images

Next, we'll add in our images to make the presentation more visually appealing. Just like the text, there are also image placeholders. To add in your images, click the image icon on each slide. Your computer files pop up. Choose the image you want to add. 

4. Add in Animations

To help add professional polish to your presentation, we'll add in animations. Choose the top menu header that says Animations . From there, choose the animation that you want to have on your slides. To see what each animation looks like, choose the Preview button on the far left side of the menu.

5. Proofread Your Presentation

Often this step is skipped. We get caught up in making our design look perfect and forget to proofread our presentation. Having grammatical errors and misspelled words is the quickest way to make your presentation look unprofessional. Take the time to go over every slide in your presentation before calling it done.

5 Quick Tips To Make Virus-Themed PPT Presentations in 2024

You’ve just seen the best free and premium coronavirus slideshow templates. Now, here are a few quarantine PowerPoint ideas that'll help you design a standout presentation: 

1. Stand Out With Custom Icons and Illustrations

Custom icons and illustrations make your presentation more memorable. Not to mention, they'll make your presentation stand out. The Covid-19 PowerPoint template features modern custom vector graphics that you can use as inspiration.

2. Keep the Text to a Minimum

Don’t overwhelm your audience by adding a lot of text on your slides. This can cause them to read the slide before you’re done presenting it and they may become disengaged. Instead, keep the text to a minimum of one to three bullet points per slide.

3. Use a Professional Color Scheme

You don’t have to shy away from color in your presentation. Make sure that your color scheme is professional and doesn’t contain any clashing colors. You can draw inspiration from this modern Coronavirus Medical PowerPoint template from Envato Elements.

4. Use Charts for Complex Data and Statistics

If you've got a lot of complex data and statistics, consider using charts and infographic elements to represent them. This will make it easier for your audience to understand and absorb the information.

5. Customize the Slides With Your Photos

Using stock photos is a great way to make your presentation more memorable. But you can achieve an even better effect by including photos of you, your team, and your employees. A template like the Corona Virus PowerPoint Template has plenty of image placeholders for you to use.

Discover More Top PowerPoint Template Designs

If you want to see even more PowerPoint template examples or if you need to create a different type of presentation, look at the following template roundups:

Common PowerPoint Questions Answered (FAQ)

If you're creating a Coronavirus PPT presentation and you're not familiar with PowerPoint, you may have some questions. We've got you covered! Here are some common PowerPoint questions and their answers:

1. I'm New to PowerPoint, What Should I Know?

PowerPoint is a powerhouse presentation software. But learning just the basics of the software enables you to create a complete presentation. Check out our ultimate PowerPoint guide to learn these basics.

2. How Should I Design My Slides?

The visual hierarchy of the slides dictates the design. The arrangement of the elements on your page and how they're placed has the biggest effect on what your audience remembers. Your slide's colors, typography, and images used are major contributors to the design of your slides. 

3. Can I Collaborate on One Presentation?

PowerPoint Online makes collaboration possible. This makes it easy to delegate separate tasks that need to be completed for the presentation. For an in-depth guide on how to collaborate as a team, view the article below.

4. What Colors Should I Use In My Coronavirus PPT?

The colors that work well are blue and red. Red helps highlight the urgency and danger of the virus and blue helps build trust with your audience. If your business has a set of brand colors, then you can use these colors as well. 

5. Can I Print Out My Slides?

Yes, you can! Print out your slides may be necessary depending on where you're presenting. Check out the tutorial below for a complete guide on how to print out your slides.

Learn More About Making Great PowerPoint Presentations in 2024

The tips we shared above are only a small selection of what makes a great presentation. If you want to learn more about designing and writing great PowerPoint presentations , check out the tutorials below: 

Create a Coronavirus Presentation Quickly With Templates

If you need to create a presentation about Coronavirus or any other type of medical presentation, there's no shortage of free PowerPoint templates with a virus theme to choose from. But, if you want to make your presentation look more unique, don’t forget to check out premium templates. 

Stop by Envato Elements if you know you’ll be needing PowerPoint templates and other creative assets on the regular or if you've got multiple brands to promote. 

Editorial Note: This post has been updated with contributions from Daniel Strongin . Daniel is a freelance instructor for Envato Tuts+.

Got any suggestions?

We want to hear from you! Send us a message and help improve Slidesgo

Top searches

Trending searches

meet the teacher

30 templates

education technology

246 templates

28 templates

48 templates

412 templates

change management

6 templates

COVID-19 Infographics

It seems that you like this template, premium google slides theme, powerpoint template, and canva presentation template.

COVID-19 has been around for a year now, so it's likely that people would need to provide some statistics about its evolution. For that, you'll need charts, infographics... and that's what you'll find in this template! The slides feature backgrounds with gradients and many layouts contain editable graphs. You can try integrating these designs into our COVID-19 presentation template, as both have been devised to work well together. This is the vaccine against boring slideshows!

Features of these infographics

• 100% editable and easy to modify
• 31 different infographics to boost your presentations
• Include icons and Flaticon’s extension for further customization
• Designed to be used in Google Slides, Canva, and Microsoft PowerPoint and Keynote
• 16:9 widescreen format suitable for all types of screens
• Include information about how to edit and customize your infographics
• Supplemental infographics for the template COVID-19

How can I use the infographics?

What are the benefits of having a Premium account?

What Premium plans do you have?

What can I do to have unlimited downloads?

Combines with:

This template can be combined with this other one to create the perfect presentation:

Don’t want to attribute Slidesgo?

Gain access to over 27800 templates & presentations with premium from 1.67€/month.

Are you already Premium? Log in

Related posts on our blog

How to Add, Duplicate, Move, Delete or Hide Slides in Google Slides

How to Change Layouts in PowerPoint

How to Change the Slide Size in Google Slides

Related presentations.

Premium template

Unlock this template and gain unlimited access

• DynamicPowerPoint.com
• SignageTube.com
• SplitFlapTV.com

Coronavirus Tips PowerPoint Template

Mar 28, 2020 | Data Dashboards , DataPoint , DataPoint Real-time Screens , Healthcare

To help with the current coronavirus emergency, we have put together these free coronavirus tips Powerpoint slide templates for you to use. The slides include coronavirus prevention tips, symptoms and instructions on what to do if you have symptoms.

Feel free to adjust the templates based on your local health authority instructions and contact information. Download the templates by providing your name and email address below.

Coronavirus Tips – Symptoms

This slide shows the common coronavirus symptoms and gives patients instructions on what to do if they have symptoms so that they don’t go to the hospital or doctor in a panic and overload the local health system. You can edit this slide or add additional slides to add local phone numbers, websites or other resource information.

nice template

I would like to download and amend the COVID slides please.

Solved over chat. Now you can use the presentation. Good luck with it!

I would like to download the template as well.

Did you sign up Nicole? That should be working. Check your spam folder maybe.

Excellent template , I will use for professional and public presentations.

Great to read. Thanks.

Submit a Comment

Your email address will not be published. Required fields are marked *

Pin It on Pinterest

• StumbleUpon
• Print Friendly

< Go back to Login

Forgot Password

Please enter your registered email ID. You will receive an email message with instructions on how to reset your password.

COVID(Coronavirus)-19 Impact PowerPoint Template

Product Description:

Download the Free COVID-19 Impact PowerPoint presentation to share with your senior management and customers. COVID-19 has impacted businesses massively. Many of us are at a point in reviewing what it all means in the short and long run. To help you build business reviews and have key discussions, we have created a PowerPoint presentation for you to download and use. This is draft material and will be updated frequently. We are making it available free of cost as a small gesture from our side.

You can also view a COVID-19 Business Impact Presentation to get ideas to showcase its impact on the business.

Check out more Change Management templates   and  COVID-19 Templates . 

You May Also Like

•   Covid 19 Timeline 02 - 4x3  –  $4.99
•   Covid 19 Timeline 02 - 16x9  –  $4.99

Covid 19 Timeline 02 PowerPoint Template

Covid 19 Timeline 02 Presentation Template Use this Covid 19 Timeline 02 PowerPoint template to create visually appealing presentations in any professional setting. Its minimalistic design and ready-to-use features enhance your presentation slides ten folds. The Covid 19 Timeline 02 PPT template is professionally designed with the principles of vision sciences to capture your audience’s attention. Convey your message clearly...     read more 

•   COVID-19 Global Update Dashboard - 4x3  –  $4.99
•   COVID-19 Global Update Dashboard - 16x9  –  $4.99

COVID-19 Global Update Dashboard PowerPoint Template

COVID-19 Global Update Dashboard Presentation Template Use this COVID-19 Global Update Dashboard PowerPoint template to create visually appealing presentations in any professional setting. Its minimalistic design and ready-to-use features enhance your presentation slides ten folds. The COVID-19 Global Update Dashboard PPT template is professionally designed with the principles of vision sciences to capture your audience’s attention. Convey your message clearly...     read more 

•   COVID 19 Timeline 01 - 4x3  –  $4.99
•   COVID 19 Timeline 01 - 16x9  –  $4.99

COVID 19 Timeline 01 PowerPoint Template

COVID 19 Timeline 01 Presentation Template Use this COVID 19 Timeline 01 PowerPoint template to create visually appealing presentations in any professional setting. Its minimalistic design and ready-to-use features enhance your presentation slides ten folds. The COVID 19 Timeline 01 PPT template is professionally designed with the principles of vision sciences to capture your audience’s attention. Convey your message clearly...     read more 

•   COVID-19 Dashboard Global - 4x3  –  $4.99
•   COVID-19 Dashboard Global - 16x9  –  $4.99

COVID-19 Dashboard Global PowerPoint Template

COVID-19 Dashboard Global Presentation Template Use this COVID-19 Dashboard Global PowerPoint template to create visually appealing presentations in any professional setting. Its minimalistic design and ready-to-use features enhance your presentation slides ten folds. The COVID-19 Dashboard Global PPT template is professionally designed with the principles of vision sciences to capture your audience’s attention. Convey your message clearly with our unique...     read more 

•   Contact-Tracing-PowerPoint-Template - 4x3  –  $4.99
•   Contact-Tracing-PowerPoint-Template - 16x9  –  $4.99

Contact Tracing PowerPoint Template

Contact Tracing Presentation Template Use this Contact Tracing PowerPoint template to create visually appealing presentations in any professional setting. Its minimalistic design and ready-to-use features enhance your presentation slides ten folds. The Contact Tracing PPT template is professionally designed with the principles of vision sciences to capture your audience’s attention. Convey your message clearly with our unique set of editable...     read more 

•   COVID 19 Business Impact Presentation - 4x3  –  $19.99
•   COVID 19 Business Impact Presentation - 16x9  –  $19.99

COVID-19 Business Impact Presentation PowerPoint Template

About COVID-19 Business Impact Presentation PowerPoint Template The recent coronavirus pandemic has forced many businesses and industries to stop their activities until society can resume a normal life. As a result, most nations are seeing an economic impact. Businesses are the ones who have suffered a lot due to this outbreak. Our Covid-19 Business Impact Presentation PowerPoint template can help...     read more 

•   Change Impact Matrix Template - 4x3  –  $4.99
•   Change Impact Matrix Template - 16x9  –  $4.99

Change Impact Matrix PowerPoint Template

Change Impact Matrix Presentation Template Use this Change Impact Matrix PowerPoint template to create visually appealing presentations in any professional setting. Its minimalistic design and ready-to-use features enhance your presentation slides ten folds. The Change Impact Matrix PPT template is professionally designed with the principles of vision sciences to capture your audience’s attention. Convey your message clearly with our unique...     read more 

•   Covid-19-Timeline-05 - 4x3  –  $4.99
•   Covid-19-Timeline-05 - 16x9  –  $4.99

COVID-19 Timeline Template for PowerPoint and Google Slides 05

COVID-19 Timeline Template for PowerPoint and Google Slides 05 The Covid-19 Timeline Template shows the timeline of Covid-19 symptoms and treatments over 22 days. The timeline shows the days from day 01 to day 22, making it clear how symptoms and treatments change over time. On the left side of the slide, there is a column where different symptoms are...     read more 

Recommended for you

•   Change Impact Assemment Matrix - 4x3  –  $6.99
•   Change Impact Assemment Matrix - 16x9  –  $6.99

Change Impact Assemment Matrix PowerPoint Template

Change Impact Assessment Matrix Presentation Template Use this Change Impact Assessment Matrix PowerPoint template to create visually appealing presentations in any professional setting. Its minimalistic design and ready-to-use features enhance your presentation slides ten folds. The Change Impact Assessment Matrix PPT template is professionally designed with the principles of vision sciences to capture your audience’s attention. Convey your message clearly...     read more 

•   Covid 19 Timeline 04 - 4x3  –  $6.99
•   Covid 19 Timeline 04 - 16x9  –  $6.99

COVID-19 Timeline Template for PowerPoint and Google Slides 04

COVID-19 Timeline Template for PowerPoint and Google Slides 04 The COVID-19 Timeline Template is meant to track and present a timeline of important events related to the COVID-19 pandemic. It includes a timeline for key dates, milestones, and actions taken during the early stages of the outbreak. This template can be really helpful for educational, informational, or reporting purposes. The...     read more 

•   Covid 19 Timeline 03 - 4x3  –  $4.99
•   Covid 19 Timeline 03 - 16x9  –  $4.99

Covid 19 Timeline 03 PowerPoint Template

Covid 19 Timeline 03 Presentation Template Use this Covid 19 Timeline 03 PowerPoint template to create visually appealing presentations in any professional setting. Its minimalistic design and ready-to-use features enhance your presentation slides ten folds. The Covid 19 Timeline 03 PPT template is professionally designed with the principles of vision sciences to capture your audience’s attention. Convey your message clearly...     read more 

•   COVID Business Impact Grid Matrix - 4x3  –  $4.99
•   COVID Business Impact Grid Matrix - 16x9  –  $4.99

COVID Business Impact Grid Matrix PowerPoint Template

COVID Business Impact Grid Matrix Presentation Template Use this COVID Business Impact Grid Matrix PowerPoint template to create visually appealing presentations in any professional setting. Its minimalistic design and ready-to-use features enhance your presentation slides ten folds. The COVID Business Impact Grid Matrix PPT template is professionally designed with the principles of vision sciences to capture your audience’s attention. Convey...     read more 

•   Change Management KPI Metrics - 4x3  –  $6.99
•   Change Management KPI Metrics - 16x9  –  $6.99

Change Management KPI Metrics PowerPoint Template

Change Management KPI Metrics Presentation Template Use this Change Management KPI Metrics PowerPoint template to create visually appealing presentations in any professional setting. Its minimalistic design and ready-to-use features enhance your presentation slides ten folds. The Change Management KPI Metrics PPT template is professionally designed with the principles of vision sciences to capture your audience’s attention. Convey your message clearly...     read more 

2 Steps Business 1 PowerPoint Template

Free 2 Steps Business 1 Presentation Template Use this Free 2 Steps Business 1 PowerPoint template to create visually appealing presentations in any professional setting. Its minimalistic design and ready-to-use features enhance your presentation slides ten folds. The Free 2 Steps Business 1 PPT template is professionally designed with the principles of vision sciences to capture your audience’s attention. Convey...     read more 

Business Steps 8 PowerPoint Template

Free Business Steps 8 Presentation Template Use this Free Business Steps 8 PowerPoint template to create visually appealing presentations in any professional setting. Its minimalistic design and ready-to-use features enhance your presentation slides ten folds. The Free Business Steps 8 PPT template is professionally designed with the principles of vision sciences to capture your audience’s attention. Convey your message clearly...     read more 

•   Change Managment Business Framework - 4x3  –  $4.99
•   Change Managment Business Framework - 16x9  –  $4.99

Change Managment Business Framework PowerPoint Template

Change Management Business Framework Presentation Template Use this Change Management Business Framework PowerPoint template to create visually appealing presentations in any professional setting. Its minimalistic design and ready-to-use features enhance your presentation slides ten folds. The Change Management Business Framework PPT template is professionally designed with the principles of vision sciences to capture your audience’s attention. Convey your message clearly...     read more 

Forgot Password?

Join the SlideUpLift Discount Club- A Lifetime Value

Benefits never expire and apply to the whole SlideUplift library including future additions.

Upon paying a one time fee, you will remain a Discount Clubber for a lifetime and enjoy 20% discounts on all products that you purchase à la carte from SlideUpLift.com

Privacy Overview

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

• Weill Cornell Medicine

Medicine Grand Rounds: COVID-19 presentations

A video of this lecture is available online to members of the Weill Cornell community. You will need to provide your CWID and password. Below are the PowerPoints that were included in the presentation.

Coronavirus Disease 2019 (COVID-19) Clinical Presentation

• Author: David J Cennimo, MD, FAAP, FACP, FIDSA, AAHIVS; Chief Editor: Michael Stuart Bronze, MD  more...
• Sections Coronavirus Disease 2019 (COVID-19)
• Practice Essentials
• Route of Transmission
• Epidemiology
• Physical Examination
• Complications
• Approach Considerations
• Laboratory Studies
• CT Scanning
• Chest Radiography
• Medical Care
• Antiviral Agents
• Immunomodulators and Other Investigational Therapies
• Investigational Antibody-Directed Therapies
• Antithrombotics
• Renin Angiotensin System Blockade and COVID-19
• Diabetes and COVID-19
• Therapies Determined Ineffective
• QT Prolongation with Potential COVID-19 Pharmacotherapies
• Investigational Devices
• Guidelines Summary
• CDC Evaluating and Testing Persons Under Investigation (PUI) for COVID-19 Clinical Guidelines
• CDC Sample Collection and Testing Guidelines for COVID-19
• Guidance for Hospitals on Containing Spread of COVID-19
• American Academy of Pediatrics Guidance on Management of Infants Born to Mothers with COVID-19
• NIH Coronavirus Disease 2019 (COVID-19) Treatment Guidelines
• Infectious Diseases Society of America (IDSA) Management Guidelines
• Thromboembolism Prevention and Treatment
• Medication Summary
• Corticosteroids
• Immunomodulators
• Complement Inhibitors
• COVID-19, Monoclonal Antibodies
• Questions & Answers
• Media Gallery

Presentations of COVID-19 range from asymptomatic/mild symptoms to severe illness and mortality. Common symptoms include fever, cough, and shortness of breath. [ 100 ]  Other symptoms, such as malaise and respiratory distress, also have been described. [ 90 ]

Symptoms may develop 2 days to 2 weeks after exposure to the virus. [ 100 ]  A pooled analysis of 181 confirmed cases of COVID-19 outside Wuhan, China, found the mean incubation period was 5.1 days, and that 97.5% of individuals who developed symptoms did so within 11.5 days of infection. [ 101 ]  

Symptom rebound and viral rebound have been described in patients (with or without antiviral treatment). In untreated patients, those (n = 563) receiving placebo in the ACTIV-2/A5401 (Adaptive Platform Treatment Trial for Outpatients with COIVD-19) platform trial recorded 13 symptoms daily between days 1 and 28. Symptom rebound was identified in 26% of participants at a median of 11 days after initial symptom onset. Viral rebound was detected in 31% and high-level viral rebound in 13% of participants. [ 102 ]  

The following symptoms may indicate COVID-19 [ 100 ] :

• Fever or chills
• Shortness of breath or difficulty breathing
• Muscle or body aches
• New loss of taste or smell
• Sore throat
• Congestion or runny nose
• Nausea or vomiting

Other reported symptoms include the following:

• Sputum production
• Respiratory distress
• Neurologic (eg, headache, altered mentality) 

Wu and McGoogan reported that, among 72,314 COVID-19 cases reported to the CCDC, 81% were mild (absent or mild pneumonia), 14% were severe (hypoxia, dyspnea, >50% lung involvement within 24-48 hours), 5% were critical (shock, respiratory failure, multiorgan dysfunction), and 2.3% were fatal. [ 103 ] These general symptom distributions have been reconfirmed across multiple observations. [ 104 , 105 ]

Clinicians evaluating patients with fever and acute respiratory illness should obtain information regarding travel history or exposure to an individual who recently returned from a country or US state experiencing active local transmission. [ 106 ]

Williamson and colleagues, in an analysis of 17 million patients, reaffirmed that severe COVID-19 and mortality was more common in males, older individuals, individuals in poverty, Black persons, and patients with medical conditions such as diabetes and severe asthma, among others. [ 107 ]

A multicenter observational cohort study conducted in Europe found frailty was a greater predictor of mortality than age or comorbidities. [ 108 ]

Type A blood has been suggested as a potential factor that predisposes to severe COVID-19, specifically in terms of increasing the risk for respiratory failure. Blood type O appears to confer a protective effect. [ 109 , 110 ]

Patients with suspected COVID-19 should be reported immediately to infection-control personnel at their healthcare facility and the local or state health department. CDC guidance calls for the patient to be cared for with airborne and contact precautions (including eye shield) in place. [ 22 ] Patient candidates for such reporting include those with fever and symptoms of lower respiratory illness who have travelled from Wuhan City, China, within the preceding 14 days or who have been in contact with an individual under investigation for COVID-19 or a patient with laboratory-confirmed COVID-19 in the preceding 14 days. [ 106 ]

A complete or partial loss of the sense of smell (anosmia) has been reported as a potential history finding in patients eventually diagnosed with COVID-19. [ 20 ] A phone survey of outpatients with mildly symptomatic COVID-19 found that 64.4% (130 of 202) reported any altered sense of smell or taste. [ 111 ] In a European study of 72 patients with PCR results positive for COVID-19, 53 patients (74%) reported reduced olfaction, whereas 50 patients (69%) reported a reduced sense of taste. Forty-nine patients (68%) reported both symptoms. [ 112 ]

Patients who are under investigation for COVID-19 should be evaluated in a private room with the door closed (an airborne infection isolation room is ideal) and asked to wear a surgical mask. All other standard contact and airborne precautions should be observed, and treating healthcare personnel should wear eye protection. [ 22 ]

The most common serious manifestation of COVID-19 upon initial presentation is pneumonia. Fever, cough, dyspnea, and abnormalities on chest imaging are common in these cases. [ 113 , 114 , 115 , 116 ]

Huang and colleagues found that, among patients with pneumonia, 99% had fever, 70% reported fatigue, 59% had dry cough, 40% had anorexia, 35% experienced myalgias, 31% had dyspnea, and 27% had sputum production. [ 113 ]

Complications of COVID-19 include  pneumonia ,  acute respiratory distress syndrome , cardiac injury, arrhythmia,  septic shock , liver dysfunction,  acute kidney injury , and multi-organ failure, among others.

Approximately 5% of patients with COVID-19, and 20% of those hospitalized, experience severe symptoms necessitating intensive care. The common complications among hospitalized patients include pneumonia (75%), ARDS (15%), AKI (9%), and acute liver injury (19%). Cardiac injury has been increasingly noted, including troponin elevation, acute heart failure, dysrhythmias, and myocarditis. Ten percent to 25 percent of hospitalized patients with COVID-19 experience prothrombotic coagulopathy resulting in venous and arterial thromboembolic events. Neurologic manifestations include impaired consciousness and stroke.

ICU case fatality is reported up to 40%. [ 104 ]  

As the COVID-19 pandemic has matured, more patients have reported long-term, post-infection sequelae. Most patients recover fully, but those who do not have reported adverse symptoms such as fatigue, dyspnea, cough, anxiety, depression, inability to focus (ie, “brain fog”), gastrointestinal problems, sleep difficulties, joint pain, and chest pain lasting weeks to months after the acute illness. Long-term studies are underway to understand the nature of these complaints. [ 117 ]  

Post-acute sequelae of SARS-CoV-2 (PASC) infection is the medical term for what is commonly called long COVID or "long haulers". The NIH includes discussion of persistent symptoms or organ dysfunction after acute COVID-19 within guidelines that discuss the clinical spectrum of the disease. [ 118 ]  

The UK National Institute for Health and Care Excellence (NICE) issued guidelines on care of long COVID that define the syndrome as: signs and symptoms that develop during or after an infection consistent with COVID-19, continue for more than 12 weeks, and are not explained by an alternative diagnosis. [ 119 ]  

Please see Long COVID-19 .

Future public health implications

Public health implications for long COVID need to be examined, as reviewed by Datta et al. As with other infections (eg, Lyme disease, syphilis, Ebola), late inflammatory and virologic sequelae may emerge. Accumulation of evidence beyond the acute infection and postacute hyperinflammatory illness is important to evaluate to gain a better understanding of the full spectrum of the disease. [ 120 ]  

Thrombotic manifestations of severe COVID-19 are caused by the ability of SARS-CoV-2 to invade endothelial cells via angiotensin-converting enzyme-2 (ACE-2), which is expressed on the surface of endothelial cells. Subsequent endothelial inflammation, complement activation, thrombin generation, platelet and leukocyte recruitment, and the initiation of innate and adaptive immune responses culminate in immunothrombosis, and can ultimately cause microthrombotic complications (eg, DVT, PE, stroke). [ 121 ]  

Kotecha et al describe patterns of myocardial injury in hospitalized patients with severe COVID-19 who had elevated troponin levels. During convalescence, myocarditis-like injury was observed, with limited extent and minimal functional consequence. However, in a proportion of patients, there was evidence of possible ongoing localized inflammation. Roughly 25% of patients had ischemic heart disease, of which two thirds had no previous history. [ 122 ]  

Reinfection

COVID-19 reinfection is defined as an infected person who has undergone full vaccination, whether they have had a booster or boosters. According to the CDC, reinfection is COVID-19 infection of an individual with 2 different viral strains that occurs at least 45 days apart. It also may occur when an individual has 2 positive CoV-2 RT-PCR tests with negative tests between the 2 positive tests. [ 123 ]

It is essential to determine reinfection rates to establish the effectiveness of current vaccine prophylaxis. Reinfection in vaccinated and non-vaccinated persons probably is due to a variant. [ 123 , 124 ]  

It is important to differentiate reinfection from reactivation or relapse of the virus, which occurs in a clinically recovered person within the first 4 weeks of infection, during which viral RNA testing has remained positive. During relapse, a tiny viral load of dormant virus reactivates, the reason of which often is unclear.

The only way to prove this state is to show that genetic samples taken at the beginning and at the time of reactivation differ genetically; such testing is unusual at the beginning of a person’s illness.

For more information, see COVID-19 Reinfections

CDC. 2019 Novel Coronavirus, Wuhan, China. CDC. Available at https://www.cdc.gov/coronavirus/2019-ncov/about/index.html . Aug. 11, 2022; Accessed: February 20, 2024.

Gallegos A. WHO Declares Public Health Emergency for Novel Coronavirus. Medscape Medical News. Available at https://www.medscape.com/viewarticle/924596 . January 30, 2020; Accessed: February 29, 2024.

Ramzy A, McNeil DG. W.H.O. Declares Global Emergency as Wuhan Coronavirus Spreads. The New York Times. Available at https://nyti.ms/2RER70M . January 30, 2020; Accessed: February 29, 2024.

The New York Times. Coronavirus Live Updates: W.H.O. Declares Pandemic as Number of Infected Countries Grows. The New York Times. Available at https://www.nytimes.com/2020/03/11/world/coronavirus-news.html#link-682e5b06 . March 11, 2020; Accessed: February 29, 2024.

Coronavirus Updates: The Illness Now Has a Name: COVID-19. The New York Times. Available at https://www.nytimes.com/2020/02/11/world/asia/coronavirus-china.html . February 11, 2020; Accessed: February 29, 2024.

WHO Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. Available at https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020 . February 11, 2020; Accessed: February 29, 2024.

Gorbalenya AE. Severe acute respiratory syndrome-related coronavirus – The species and its viruses, a statement of the Coronavirus Study Group. Available at https://read.qxmd.com/doi/10.1101/2020.02.07.937862 . February 11, 2020; Accessed: February 29, 2024.

CDC COVID-19 Response Team, Jorden MA, Rudman SL, et al. Evidence for Limited Early Spread of COVID-19 Within the United States, January-February 2020. MMWR. Available at https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments . May 29, 2020; Accessed: February 29, 2024.

End of the Federal COVID-19 Public Health Emergency (PHE) Declaration. CDC Centers for Disease Control and Prevention. Available at https://www.cdc.gov/coronavirus/2019-ncov/your-health/end-of-phe.html . 2023 May 05; Accessed: February 29, 2024.

CDC. Coronavirus Disease 2019 (COVID-19): Recommendations for Cloth Face Covers. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover.html . April 3, 2020; Accessed: February 29, 2024.

Ferguson NM, Laydon D, Nedjati-Gilani G, Imai N, Ainslie K, Baguelin M, et al. Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. Imperial College COVID-19 Response Team. Available at https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-College-COVID19-NPI-modelling-16-03-2020.pdf . 2020 Mar 16; Accessed: February 29, 2024.

Christie A, Brooks JT, Hicks LA, et al. Guidance for Implementing COVID-19 Prevention Strategies in the Context of Varying Community Transmission Levels and Vaccination Coverage. MMWR Morb Mortal Wkly Rep . 2021. 70:1044–1047. [Full Text] .

Honein MA, Christie A, Rose DA, et al. Summary of guidance for public health strategies to address high levels of community transmission of SARS-CoV-2 and related deaths, December 2020. MMWR Morb Mortal Wkly Rep . 2020 Dec 04. [Full Text] .

Centers for Disease Control and Prevention. How to Protect Yourself & Others. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html . November 29, 2021; Accessed: February 29, 2024.

CDC. Underlying medical conditions associated with high risk for severe COVID-19: Information for healthcare providers. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html . 2021 Mar 29; updated Feb. 9, 2023; Accessed: February 29, 2024.

Tanaka H, Ogata T, Shibata T, Nagai H, Takahashi Y, Kinoshita M, et al. Shorter Incubation Period among COVID-19 Cases with the BA.1 Omicron Variant. Int J Environ Res Public Health . 2022 May 23. 19 (10): [QxMD MEDLINE Link] .

Clinical characteristics of COVID-19. European Centre for Disease Prevention and Control. Available at https://www.ecdc.europa.eu/en/covid-19/latest-evidence/clinical . Updated: 30 May 2023; Accessed: February 20, 2024.

Hentsch L, Cocetta S, Allali G, Santana I, Eason R, Adam E, et al. Breathlessness and COVID-19: A Call for Research. Respiration . 2021. 100 (10):1016-1026. [QxMD MEDLINE Link] .

Zoghi G, Moosavy SH, Yavarian S, HasaniAzad M, Khorrami F, Sharegi Brojeni M, et al. Gastrointestinal implications in COVID-19. BMC Infect Dis . 2021 Nov 4. 21 (1):1135. [QxMD MEDLINE Link] .

Rabin RC. Lost Sense of Smell May Be Peculiar Clue to Coronavirus Infection. The New York Times. Available at https://www.nytimes.com/2020/03/22/health/coronavirus-symptoms-smell-taste.html . March 22, 2020; Accessed: February 29, 2024.

Coelho DH, Reiter ER, French E, Costanzo RM. Decreasing Incidence of Chemosensory Changes by COVID-19 Variant. Otolaryngol Head Neck Surg . 2022 May 3. 1945998221097656. [QxMD MEDLINE Link] .

CDC. 2019 Novel Coronavirus, Wuhan, China: Interim Healthcare Infection Prevention and Control Recommendations for Patients Under Investigation for 2019 Novel Coronavirus. CDC. Available at https://www.cdc.gov/coronavirus/2019-ncov/infection-control.html . January 18, 2020; Accessed: December 1, 2021.

Rizk JG, Forthal DN, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, et al. Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic. Drug Discov Today . 2020 Nov 27. [QxMD MEDLINE Link] . [Full Text] .

Abutaleb Y. How the new coronavirus differs from SARS, measles and Ebola. The Washington Post. Available at https://www.washingtonpost.com/health/how-the-new-coronavirus-differs-from-sars-measles-and-ebola/2020/01/23/aac6bb06-3e1b-11ea-b90d-5652806c3b3a_story.html . January 23, 2020; Accessed: February 20, 2024.

World Health Organization. MERS situation update, February 2022. WHO Regional Office for the Eastern Mediterranean. Available at http://www.emro.who.int/health-topics/mers-cov/mers-outbreaks.html . February 2022; Accessed: May 17, 2022.

WHO. Leading health agencies outline updated terminology for pathogens that transmit through the air. News Release. World Health Organization. Available at https://www.who.int/news/item/18-04-2024-leading-health-agencies-outline-updated-terminology-for-pathogens-that-transmit-through-the-air . April 18, 2024; Accessed: April 25, 2024.

Handiso TB, Jifar MS, Nuriye Hagisso S. Coronavirus's (SARS-CoV-2) airborne transmission. SAGE Open Med . 2022. 10:20503121221094185. [QxMD MEDLINE Link] .

Centers for Disease Control and Prevention. COVID-19 Overview and Infection Prevention and Control Priorities in non-U.S. Healthcare Settings. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/coronavirus/2019-ncov/hcp/non-us-settings/overview/index.html . Updated Oct 27, 2023; Accessed: February 29, 2024.

CDC. Coronavirus Disease 2019: Scientific Brief: SARS-CoV-2 and Potential Airborne Transmission. Centers for Disease Control and Prevention. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/coronavirus/2019-ncov/more/scientific-brief-sars-cov-2.html . 2020 Oct 05; Accessed: December 1, 2021.

Morawska L, Milton DK. It is Time to Address Airborne Transmission of COVID-19. Clin Infect Dis . 2020 Jul 6. [QxMD MEDLINE Link] .

Mask use in the context of COVID-19 (1 December 2020). World Health Organization. Available at https://www.who.int/publications/i/item/advice-on-the-use-of-masks-in-the-community-during-home-care-and-in-healthcare-settings-in-the-context-of-the-novel-coronavirus-(2019-ncov)-outbreak . December 1, 2020; Accessed: February 29, 2024.

van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med . 2020 Mar 17. [QxMD MEDLINE Link] .

Chin AWH, Chu JTS, Perera MRA, et al. Stability of SARS-CoV-2 in different environmental conditions. The Lancet Microbe . April 2, 2020. [Full Text] .

Rahmani A, Dini G, Leso V, Montecucco A, Kusznir Vitturi B, Iavicoli I, et al. Duration of SARS-CoV-2 shedding and infectivity in the working age population: a systematic review and meta-analysis. Med Lav . 2022 Apr 26. 113 (2):e2022014. [QxMD MEDLINE Link] .

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet . 2020 Mar 11. [QxMD MEDLINE Link] .

Liu Y, Yan LM, Wan L, Xiang TX, Le A, Liu JM, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis . 2020 Mar 19. [QxMD MEDLINE Link] .

Zhou B, She J, Wang Y, Ma X. The duration of viral shedding of discharged patients with severe COVID-19. Clin Infect Dis . 2020 Apr 17. [QxMD MEDLINE Link] .

Mole B. Recovered COVID-19 patients test positive but not infectious, data finds. Ars Technica. Available at https://arstechnica.com/science/2020/05/feared-reactivation-of-covid-19-infections-disputed-by-new-data/ . May 19, 2020; Accessed: February 29, 2024.

Aydillo T, Gonzalez-Reiche AS, Aslam S, van de Guchte A, Khan Z, Obla A, et al. Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer. N Engl J Med . 2020 Dec 24. 383 (26):2586-2588. [QxMD MEDLINE Link] . [Full Text] .

Baang JH, Smith C, Mirabelli C, Valesano AL, Manthei DM, Bachman M, et al. Prolonged SARS-CoV-2 replication in an immunocompromised patient. J Infect Dis . 2020 Oct 22. [QxMD MEDLINE Link] . [Full Text] .

Li D, Jin M, Bao P, Zhao W, Zhang S. Clinical Characteristics and Results of Semen Tests Among Men With Coronavirus Disease 2019. JAMA Netw Open . 2020 May 1. 3 (5):e208292. [QxMD MEDLINE Link] .

Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative Review. Ann Intern Med . 2020 Sep 1. 173 (5):362-367. [QxMD MEDLINE Link] . [Full Text] .

Johansson MA, Quandelacy TM, Kada S, Prasad PV, Steele M, Brooks JT, et al. SARS-CoV-2 Transmission From People Without COVID-19 Symptoms. JAMA Netw Open . 2021 Jan 4. 4 (1):e2035057. [QxMD MEDLINE Link] . [Full Text] .

Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med . 2020 Feb 19. [QxMD MEDLINE Link] .

WHO Coronavirus Disease (COVID-19) Dashboard. World Health Organization. Available at https://covid19.who.int/ . 2023 Apr 05; Accessed: February 29, 2024.

CDC. Coronavirus Disease 2019 (COVID-19) – Cases in the U.S. Centers for Disease Control and Prevention (CDC). Available at https://covid.cdc.gov/covid-data-tracker/#cases_casesper100klast7days . 2023 Mar 29; Accessed: April 5, 2023.

Ahmad FB, Cisewski JA, Miniño A, Anderson RN. Provisional Mortality Data - United States, 2020. MMWR Morb Mortal Wkly Rep . 2021 Apr 9. 70 (14):519-522. [QxMD MEDLINE Link] . [Full Text] .

Ahmad FB, Cisewski JA, Anderson RN. Provisional Mortality Data - United States, 2021. MMWR Morb Mortal Wkly Rep . 2022 Apr 29. 71 (17):597-600. [QxMD MEDLINE Link] . [Full Text] .

Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and Mortality among Black Patients and White Patients with Covid-19. N Engl J Med . 2020 Jun 25. 382 (26):2534-2543. [QxMD MEDLINE Link] . [Full Text] .

Khanijahani A, Iezadi S, Gholipour K, Azami-Aghdash S, Naghibi D. A systematic review of racial/ethnic and socioeconomic disparities in COVID-19. Int J Equity Health . 2021 Nov 24. 20 (1):248. [QxMD MEDLINE Link] .

Zelner J, Trangucci R, Naraharisetti R, Cao A, Malosh R, Broen K, et al. Racial disparities in COVID-19 mortality are driven by unequal infection risks. Clin Infect Dis . 2020 Nov 21. [QxMD MEDLINE Link] . [Full Text] .

Tai DBG, Shah A, Doubeni CA, Sia IG, Wieland ML. The Disproportionate Impact of COVID-19 on Racial and Ethnic Minorities in the United States. Clin Infect Dis . 2020 Jun 20. [QxMD MEDLINE Link] . [Full Text] .

Millet C, Racoosin E, Narvar S, Horani G, et al. The Racial Divide: A Follow Up Study on Racial Disparity Amongst COVID-19 Survivors in an Urban Community. J Community Hosp Intern Med Perspect . 2022 May 2. 12(3):66-70. [QxMD MEDLINE Link] . [Full Text] .

Hobbs CV, Kim SS, Vemula P, Inagaki K, et al. Active Surveillance With Seroprevalence-based Infection Rates Indicates Racial Disparities With Pediatric SARS-CoV-2 Requiring Hospitalization in Mississippi, March 2020-February 2021. Pediatr Infect Dis J . 2022 Jun 7. [QxMD MEDLINE Link] .

Ward LA, Black KP, Britton CL, Tompkins ML, Provost EM. COVID-19 Cases, Hospitalizations, and Deaths Among American Indian or Alaska Native Persons - Alaska, 2020-2021. MMWR Morb Mortal Wkly Rep . 2022 Jun 3. 71 (22):730-733. [QxMD MEDLINE Link] .

Cunningham JW, Vaduganathan M, Claggett BL, Jering KS, Bhatt AS, Rosenthal N, et al. Clinical Outcomes in Young US Adults Hospitalized With COVID-19. JAMA Intern Med . 2020 Sep 9. [QxMD MEDLINE Link] . [Full Text] .

Park YJ, Choe YJ, Park O, and the, COVID-19 National Emergency Response Center, Epidemiology and Case Management Team. Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020. Emerg Infect Dis . 2020 Oct. 26 (10):2465-2468. [QxMD MEDLINE Link] . [Full Text] .

Schwartz NG, Moorman AC, Makaretz A, Chang KT, Chu VT, Szablewski CM, et al. Adolescent with COVID-19 as the Source of an Outbreak at a 3-Week Family Gathering - Four States, June-July 2020. MMWR Morb Mortal Wkly Rep . 2020 Oct 9. 69 (40):1457-1459. [QxMD MEDLINE Link] . [Full Text] .

Zhu F, Ang JY. COVID-19 Infection in Children: Diagnosis and Management. Curr Infect Dis Rep . 2022 Apr 11. 1-12. [QxMD MEDLINE Link] .

Waghmare A, Hijano DR. SARS-CoV-2 Infection and COVID-19 in Children. Clin Chest Med . 2023 Jun. 44 (2):359-371. [QxMD MEDLINE Link] .

Castagnoli R, Votto M, Licari A, Brambilla I, Bruno R, Perlini S, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Children and Adolescents: A Systematic Review. JAMA Pediatr . 2020 Apr 22. [QxMD MEDLINE Link] .

Aronoff SC, Hall A, Del Vecchio MT. The Natural History of SARS-Cov-2 Related Multisystem Inflammatory Syndrome in Children (MIS-C): A Systematic Review. J Pediatric Infect Dis Soc . 2020 Sep 14. [QxMD MEDLINE Link] . [Full Text] .

Hoang A, Chorath K, Moreira A, Evans M, Burmeister-Morton F, Burmeister F, et al. COVID-19 in 7780 pediatric patients: A systematic review. EClinicalMedicine . 2020 Jul. 24:100433. [QxMD MEDLINE Link] . [Full Text] .

Ahmed M, Advani S, Moreira A, Zoretic S, Martinez J, Chorath K, et al. Multisystem inflammatory syndrome in children: A systematic review. EClinicalMedicine . 2020 Sep 4. 100527. [QxMD MEDLINE Link] . [Full Text] .

Children and COVID-19: State-Level Data Report. American Academy of Pediatrics. Available at https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/ . 2022 Oct 27; Accessed: November 7, 2022.

Hillis SD, Blenkinsop A, Villaveces A, Annor FB, Liburd L, Massetti GM, et al. COVID-19-Associated Orphanhood and Caregiver Death in the United States. Pediatrics . 2021 Oct 7. [QxMD MEDLINE Link] . [Full Text] .

CDC. COVID Data Tracker. Centers for Disease Control and Prevention. Available at https://covid.cdc.gov/covid-data-tracker/#datatracker-home . May 11, 2023; Accessed: March 6, 2024.

Bixler D, Miller AD, Mattison CP, and the, Pediatric Mortality Investigation Team. SARS-CoV-2-Associated Deaths Among Persons Aged MMWR Morb Mortal Wkly Rep</i>. 2020 Sep 18. 69 (37):1324-1329. [QxMD MEDLINE Link] . [Full Text] .

Chao JY, Derespina KR, Herold BC, Goldman DL, Aldrich M, Weingarten J, et al. Clinical Characteristics and Outcomes of Hospitalized and Critically Ill Children and Adolescents with Coronavirus Disease 2019 at a Tertiary Care Medical Center in New York City. J Pediatr . 2020 Aug. 223:14-19.e2. [QxMD MEDLINE Link] . [Full Text] .

Han MS, Choi EH, Chang SH, Jin BL, Lee EJ, Kim BN, et al. Clinical Characteristics and Viral RNA Detection in Children With Coronavirus Disease 2019 in the Republic of Korea. JAMA Pediatr . 2020 Aug 28. [QxMD MEDLINE Link] . [Full Text] .

Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis . 2020 Nov. 20 (11):e276-e288. [QxMD MEDLINE Link] .

Feldstein LR, Tenforde MW, Friedman KG, and the, Overcoming COVID-19 Investigators. Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19. JAMA . 2021 Feb 24. [QxMD MEDLINE Link] . [Full Text] .

Ko JY, DeSisto CL, Simeone RM, Ellington S, Galang RR, Oduyebo T, et al. Adverse Pregnancy Outcomes, Maternal Complications, and Severe Illness Among US Delivery Hospitalizations With and Without a Coronavirus Disease 2019 (COVID-19) Diagnosis. Clin Infect Dis . 2021 Jul 15. 73 (Suppl 1):S24-S31. [QxMD MEDLINE Link] . [Full Text] .

Wang H, Li N, Sun C, Guo X, Su W, Song Q, et al. The association between pregnancy and COVID-19: A systematic review and meta-analysis. Am J Emerg Med . 2022 Apr 6. 56:188-195. [QxMD MEDLINE Link] .

Ayala-Ramírez P, González M, Escudero C, Quintero-Arciniegas L, Giachini FR, Alves de Freitas R, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Pregnancy. A Non-systematic Review of Clinical Presentation, Potential Effects of Physiological Adaptations in Pregnancy, and Placental Vascular Alterations. Front Physiol . 2022. 13:785274. [QxMD MEDLINE Link] .

DeSisto CL, Wallace B, Simeone RM, Polen K, Ko JY, Meaney-Delman D, et al. Risk for Stillbirth Among Women With and Without COVID-19 at Delivery Hospitalization - United States, March 2020-September 2021. MMWR Morb Mortal Wkly Rep . 2021 Nov 26. 70 (47):1640-1645. [QxMD MEDLINE Link] . [Full Text] .

Marín Gabriel MA, Reyne Vergeli M, Caserío Carbonero S, Sole L, Carrizosa Molina T, Rivero Calle I, et al. Maternal, Perinatal and Neonatal Outcomes With COVID-19: A Multicenter Study of 242 Pregnancies and Their 248 Infant Newborns During Their First Month of Life. Pediatr Infect Dis J . 2020 Sep 11. [QxMD MEDLINE Link] .

Pierce-Williams RAM, Burd J, Felder L, Khoury R, Bernstein PS, Avila K, et al. Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies: a United States cohort study. Am J Obstet Gynecol MFM . 2020 Aug. 2 (3):100134. [QxMD MEDLINE Link] . [Full Text] .

Adhikari EH, Moreno W, Zofkie AC, MacDonald L, McIntire DD, Collins RRJ, et al. Pregnancy Outcomes Among Women With and Without Severe Acute Respiratory Syndrome Coronavirus 2 Infection. JAMA Netw Open . 2020 Nov 2. 3 (11):e2029256. [QxMD MEDLINE Link] .

Chambers C, Krogstad P, Bertrand K, Contreras D, Tobin NH, Bode L, et al. Evaluation for SARS-CoV-2 in Breast Milk From 18 Infected Women. JAMA . 2020 Aug 19. [QxMD MEDLINE Link] . [Full Text] .

Pace RM, Williams JE, Järvinen KM, Meehan CL, Martin MA, Ley SH, et al. Milk From Women Diagnosed With COVID-19 Does Not Contain SARS-CoV-2 RNA but Has Persistent Levels of SARS-CoV-2-Specific IgA Antibodies. Front Immunol . 2021. 12:801797. [QxMD MEDLINE Link] . [Full Text] .

Dandachi D, Geiger G, Montgomery MW, and the, HIV-COVID-19 consortium. Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients with HIV and Coronavirus Disease-19. Clin Infect Dis . 2020 Sep 9. [QxMD MEDLINE Link] . [Full Text] .

Okoh AK, Bishburg E, Grinberg S, Nagarakanti S. COVID-19 Pneumonia in Patients With HIV: A Case Series. J Acquir Immune Defic Syndr . 2020 Sep 1. 85 (1):e4-e5. [QxMD MEDLINE Link] . [Full Text] .

Karmen-Tuohy S, Carlucci PM, Zervou FN, Zacharioudakis IM, Rebick G, Klein E, et al. Outcomes Among HIV-Positive Patients Hospitalized With COVID-19. J Acquir Immune Defic Syndr . 2020 Sep 1. 85 (1):6-10. [QxMD MEDLINE Link] . [Full Text] .

Ho HE, Peluso MJ, Margus C, Matias Lopes JP, He C, Gaisa MM, et al. Clinical outcomes and immunologic characteristics of Covid-19 in people with HIV. J Infect Dis . 2020 Jun 30. [QxMD MEDLINE Link] . [Full Text] .

Oyelade T, Alqahtani JS, Hjazi AM, Li A, Kamila A, Raya RP. Global and Regional Prevalence and Outcomes of COVID-19 in People Living with HIV: A Systematic Review and Meta-Analysis. Trop Med Infect Dis . 2022 Feb 3. 7 (2): [QxMD MEDLINE Link] .

Self WH, Tenforde MW, Stubblefield WB, and the, CDC COVID-19 Response Team IVY Network. Seroprevalence of SARS-CoV-2 among frontline health care personnel in a multistate hospital network – 13 academic medical centers, April-June 2020. MMWR Morb Mortal Wkly Rep . 2020 Aug 31. 69: [Full Text] .

Barron E, Bakhai C, Kar P, Weaver A, Bradley D, Ismail H, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol . 2020 Aug 13. [QxMD MEDLINE Link] . [Full Text] .

O'Hearn M, Liu J, Cudhea F, Micha R, Mozaffarian D. Coronavirus Disease 2019 Hospitalizations Attributable to Cardiometabolic Conditions in the United States: A Comparative Risk Assessment Analysis. J Am Heart Assoc . 2021 Feb. 10 (5):e019259. [QxMD MEDLINE Link] . [Full Text] .

Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis . 2020 Jan 14. 91:264-266. [QxMD MEDLINE Link] .

Vangeel L, De Jonghe S, Maes P, Slechten B, Raymenants J, André E, et al. Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 omicron and other variants of concern. bioRxiv . 2021 Dec 28. [Full Text] .

Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. medRxiv . 2021 Dec 02. [Full Text] .

Wilhelm A, Widera M, Grikscheit K, Toptan T, Schenk B, Pallas C, et al. Reduced neutralization of SARS-CoV-2 omicron variant by vaccine sera and monoclonal antibodies. medRxiv . 2021 Dec 13. [Full Text] .

Cherian S, Potdar V, Jadhav S, Yadav P, Gupta N, Das M, et al. Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. bioRxiv . 2021 May 03. [Full Text] .

Edara VV, Lai L, Sahoo MK, Floyd K, Sibai M, Solis D, et al. Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. bioRxiv . 2021 May 10. [Full Text] .

Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med . 2021 Jul 21. [QxMD MEDLINE Link] . [Full Text] .

Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. Report 42 - Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. Imperial College London, MRC Centre for Global Infectious Disease Analysis. Available at https://www.imperial.ac.uk/media/imperial-college/medicine/mrc-gida/2020-12-31-COVID19-Report-42-Preprint-VOC.pdf . 2020 Dec 31; Accessed: December 1, 2021.

Nelson G, Oleksandr B, Spilman P, Niazi K, Rabizadeh S, Soon-Shiong P. Molecular dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of E484K, K417N and N401Y mutations (501Y.V2 variant) induces conformational change greater than N401Y mutant alone, potentially resulting in an escape mutant. bioRxiv . 2021 Jan 13. [Full Text] .

Sabino EC, Buss LF, Carvalho MPS, Prete CA, Crispim MAE, Fraiji NA, et al. Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. Lancet . 2021 Jan 27. [Full Text] .

CDC. Symptoms of Coronavirus. CDC. Available at https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html . May 13, 2020 (updated March 22, 2022); Accessed: April 29, 2022.

Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med . 2020 Mar 10. [QxMD MEDLINE Link] .

Deo R, Choudhary MC, Moser C, and the, ACTIV-2/A5401 Study Team†. Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection. Ann Intern Med . 2023 Feb 21. [QxMD MEDLINE Link] . [Full Text] .

Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA . 2020 Feb 24. [QxMD MEDLINE Link] .

Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA . 2020 Aug 25. 324 (8):782-793. [QxMD MEDLINE Link] .

Burke RM, Killerby ME, Newton S, Ashworth CE, Berns AL, Brennan S, et al. Symptom Profiles of a Convenience Sample of Patients with COVID-19 - United States, January-April 2020. MMWR Morb Mortal Wkly Rep . 2020 Jul 17. 69 (28):904-908. [QxMD MEDLINE Link] .

CDC. Healthcare Workers: Information on COVID-19. CDC. Available at https://www.cdc.gov/coronavirus/2019-ncov/hcp/index.html . March 31, 2021 (updated); Accessed: December 1, 2021.

Williamson EJ, Walker AJ, Bhaskaran K, et al. OpenSAFELY: factors associated with COVID-19 death in 17 million patients. Nature . 2020 Jul 8. [QxMD MEDLINE Link] .

Hewitt J, Carter B, Vilches-Moraga A, et al. The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study. Lancet Public Health . 2020 Jun 30. [QxMD MEDLINE Link] .

Ellinghaus D, Degenhardt F, Bujanda L, et al. The ABO blood group locus and a chromosome 3 gene cluster associate with SARS-CoV-2 respiratory failure in an Italian-Spanish genome-wide association analysis. medRxiv. Available at https://www.medrxiv.org/content/10.1101/2020.05.31.20114991v1 . June 2, 2020; Accessed: December 1, 2021.

Ellinghaus D, Degenhardt F, Bujanda L, et al. Genomewide Association Study of Severe Covid-19 With Respiratory Failure. NEJM . 2020 Jun 17. [QxMD MEDLINE Link] . [Full Text] .

Spinato G, Fabbris C, Polesel J, Cazzador D, Borsetto D, Hopkins C, et al. Alterations in Smell or Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection. JAMA . 2020 Apr 22. [QxMD MEDLINE Link] .

Luers JC, Rokohl AC, Loreck N, Wawer Matos PA, Augustin M, Dewald F, et al. Olfactory and Gustatory Dysfunction in Coronavirus Disease 19 (COVID-19). Clin Infect Dis . 2020 May 1. [QxMD MEDLINE Link] .

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet . 2020 Jan 24. [QxMD MEDLINE Link] .

Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med . 2020 Feb 28. [QxMD MEDLINE Link] .

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet . 2020 Feb 15. 395 (10223):507-513. [QxMD MEDLINE Link] .

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA . 2020 Feb 7. [QxMD MEDLINE Link] .

CDC. Long-Term Effects of COVID-19. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects.html . 2020 Nov 13; Accessed: December 1, 2021.

[Guideline] COVID-19 Treatment Guidelines Panel. Clinical Spectrum of SARS-CoV-2 Infection. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/ . March 1 2024 (updated); Accessed: February 29, 2024.

[Guideline] COVID-19 rapid guideline: managing the long-term effects of COVID-19. National Institute for Health and Care Excellence (NICE). Available at https://www.nice.org.uk/guidance/NG188 . 2020 Dec 18; Accessed: December 1, 2021.

Datta SD, Talwar A, Lee JT. A Proposed Framework and Timeline of the Spectrum of Disease Due to SARS-CoV-2 Infection: Illness Beyond Acute Infection and Public Health Implications. JAMA . 2020 Dec 8. 324 (22):2251-2252. [QxMD MEDLINE Link] . [Full Text] .

McFadyen JD, Stevens H, Peter K. The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications. Circ Res . 2020 Jul 31. 127 (4):571-587. [QxMD MEDLINE Link] . [Full Text] .

Kotecha T, Knight DS, Razvi Y, Kumar K, Vimalesvaran K, Thornton G, et al. Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance. Eur Heart J . 2021 Feb 18. [QxMD MEDLINE Link] . [Full Text] .

Sciscent BY, Eisele CD, Ho L, King SD, Jain R, Golamari RR. COVID-19 reinfection: the role of natural immunity, vaccines, and variants. J Community Hosp Intern Med Perspect . 2021. 11 (6):733-739. [QxMD MEDLINE Link] .

Pérez-Lago L, Kestler M, Sola-Campoy PJ, et al. SARS-CoV-2 superinfection and reinfection with three different strains. Transbound Emerg Dis . 2021 Oct 23. [QxMD MEDLINE Link] .

CDC. 2019 Novel Coronavirus, Wuhan, China: Frequently Asked Questions and Answers. CDC. Available at https://www.cdc.gov/coronavirus/2019-ncov/faq.html . October 19, 2021; Accessed: December 1, 2021.

FDA. Coronavirus (COVID-19) Update: Daily Roundup. fda.gov. Available at https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-daily-roundup . March 23, 2020; Accessed: December 1, 2021.

Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med . 2020 Mar 13. [QxMD MEDLINE Link] .

Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis . 2020 Feb 24. [QxMD MEDLINE Link] .

Zhao W, Zhong Z, Xie X, Yu Q, Liu J. Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study. AJR Am J Roentgenol . 2020 Mar 3. 1-6. [QxMD MEDLINE Link] .

Bai HX, Hsieh B, Xiong Z, Halsey K, Choi JW, Tran TML, et al. Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT. Radiology . 2020 Mar 10. 200823. [QxMD MEDLINE Link] .

ACR. ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection. American College of Radiology. Available at https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Recommendations-for-Chest-Radiography-and-CT-for-Suspected-COVID19-Infection . March 22, 2020; Accessed: December 1, 2021.

Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci . 2020 Mar 4. [QxMD MEDLINE Link] .

Wang Y, Liu Y, Liu L, Wang X, Luo N, Ling L. Clinical outcome of 55 asymptomatic cases at the time of hospital admission infected with SARS-Coronavirus-2 in Shenzhen, China. J Infect Dis . 2020 Mar 17. [QxMD MEDLINE Link] .

Li M, Lei P, Zeng B, Li Z, Yu P, Fan B, et al. Coronavirus Disease (COVID-19): Spectrum of CT Findings and Temporal Progression of the Disease. Acad Radiol . 2020 Mar 20. [QxMD MEDLINE Link] .

Wong HYF, Lam HYS, Fong AH, Leung ST, Chin TW, Lo CSY, et al. Frequency and Distribution of Chest Radiographic Findings in COVID-19 Positive Patients. Radiology . 2019 Mar 27. 201160. [QxMD MEDLINE Link] .

Bogoch II, Watts A, Thomas-Bachli A, Huber C, Kraemer MUG, Khan K. Pneumonia of Unknown Etiology in Wuhan, China: Potential for International Spread Via Commercial Air Travel. J Travel Med . 2020 Jan 14. [QxMD MEDLINE Link] .

Veklury (remdesivir) [package insert]. Foster City, CA: Gilead Sciences, Inc. February 2024. Available at [Full Text] .

RECOVERY Collaborative Group., Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med . 2021 Feb 25. 384 (8):693-704. [QxMD MEDLINE Link] . [Full Text] .

WHO. The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with COVID-19. WHO. Available at https://www.who.int/news-room/commentaries/detail/the-use-of-non-steroidal-anti-inflammatory-drugs-(nsaids)-in-patients-with-covid-19 . April 19, 2020; Accessed: December 1, 2021.

[Guideline] Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. IDSA. Available at https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/ . 2021 Oct 01; updated 6/26/2023; Accessed: February 29, 2024.

Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, O’Mera MJ, et al. A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing. bioRxiv. Available at https://www.biorxiv.org/content/10.1101/2020.03.22.002386v1 . 2020 Mar 22; Accessed: December 1, 2021.

Arshad U, Pertinez H, Box H, Tatham L, Rajoki RKR, Curley P, et al. Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics. medRxiv . 2020 Apr 22. [Full Text] .

World Health Organization. “Solidarity” clinical trial for COVID-19 treatments. WHO. Available at https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments . 2020 Oct 16; Accessed: December 1, 2021.

WHO Solidarity Trial Consortium. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med . 2020 Dec 2. [QxMD MEDLINE Link] . [Full Text] .

Kalil AC. Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. JAMA . 2020 Mar 24. [QxMD MEDLINE Link] . [Full Text] .

Rome BN, Avorn J. Drug Evaluation during the Covid-19 Pandemic. N Engl J Med . 2020 Apr 14. [QxMD MEDLINE Link] . [Full Text] .

Frellick M. Key Drugs Join PPEs on List of Front-Line Shortages. Medscape Medical News . 2020 Apr 02. Available at https://www.medscape.com/viewarticle/928039 .

Live Updates: Which Drugs Are In Shortage Because of COVID-19?. GoodRx. Available at https://www.goodrx.com/blog/covid-19-drug-shortages-updates/ . July 13, 2020; Accessed: December 1, 2021.

Wilson FP. Hydroxychloroquine for COVID-19: What’s the Evidence? (Commentary). Medscape Medical News and Perspectives . 2020 Mar 25. Available at https://www.medscape.com/viewarticle/927342 .

CDC. Coronavirus Disease 2019 (COVID-19): Community-Related Exposures. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/coronavirus/2019-ncov/php/public-health-recommendations.html . March 1, 2021 (updated); Accessed: December 1, 2021.

CDC. Coronavirus Disease 2019 (COVID-19): Travel-Associated Exposures. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/coronavirus/2019-ncov/php/risk-assessment.html . November 5, 2021 (updated); Accessed: December 1, 2021.

Leung NHL, Chu DKW, Shiu EYC, et al. Respiratory virus shedding in exhaled breath and efficacy of face masks. Nat Med . 2020. [Full Text] .

Smith JD, MacDougall CC, Johnstone J, Copes RA, Schwartz B, Garber GE. Effectiveness of N95 respirators versus surgical masks in protecting health care workers from acute respiratory infection: a systematic review and meta-analysis. CMAJ . 2016 May 17. 188 (8):567-574. [QxMD MEDLINE Link] .

TLR 2/6/9 agonist PUL-042. NCI Drug Dictionary. Available at https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tlr-2-6-9-agonist-pul-042 . Accessed: December 1, 2021.

The Use PUL-042 Inhalation Solution to Prevent COVID-19 in Adults Exposed to SARS-CoV-2. ClinicalTrials.gov. Available at https://clinicaltrials.gov/ct2/show/NCT04313023 . 2020 Mar 24; Accessed: December 1, 2021.

The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection. ClinicalTrials.gov. Available at https://clinicaltrials.gov/ct2/show/NCT04312997?term=PUL-042&cond=COVID&cntry=US&draw=2&rank=2 . 2020 May 07; Accessed: December 1, 2021.

Holshue ML, DeBolt C, Lindquist S, and, the Washington State 2019-nCoV Case Investigation Team. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med . 2020 Mar 5. 382 (10):929-936. [QxMD MEDLINE Link] .

National Institutes of Health. NIH clinical trial of remdesivir to treat COVID-19 begins. U.S. Department of Health and Human Services. Available at https://www.nih.gov/news-events/news-releases/nih-clinical-trial-remdesivir-treat-covid-19-begins . 2020 Feb 25; Accessed: March 24, 2020.

Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med . 2020 Oct 8. [QxMD MEDLINE Link] . [Full Text] .

Harrington DP, Baden LR, Hogan JW. A Large, Simple Trial Leading to Complex Questions. N Engl J Med . 2020 Dec 2. [QxMD MEDLINE Link] . [Full Text] .

Ader F, Bouscambert-Duchamp M, Hites M, and the, DisCoVeRy Study Group. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis . 2021 Sep 14. [QxMD MEDLINE Link] . [Full Text] .

Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med . November 5, 2020. 383:1827-1837. [QxMD MEDLINE Link] . [Full Text] .

Spinner CD, Gottlieb RL, Criner GJ, and the, GS-US-540-5774 Investigators. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA . 2020 Aug 21. [QxMD MEDLINE Link] . [Full Text] .

Gottlieb RL, Vaca CE, Paredes R, and the, GS-US-540-9012 (PINETREE) Investigators. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med . 2021 Dec 22. [QxMD MEDLINE Link] . [Full Text] .

Veklury (remdesivir) reduced risk of mortality in hospitalized COVID-19 patients across all variant time periods in a real world study of more than 500,000 patients. Gilead . 2023 Jan 21. Available at https://www.gilead.com/news-and-press/press-room/press-releases/2023/2/veklury-remdesivir-reduced-risk-of-mortality-in-hospitalized-covid19-patients-across-all-variant-time-periods-in-a-real-world-study-of-more-than-5 .

Amstutz A, et al. Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomized controlled trials. Lancet Respir Med . 2023 Feb 21. [Full Text] .

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734) in Participants From Birth to < 18 Years of Age With Coronavirus Disease 2019 (COVID-19) (CARAVAN). ClinicalTrials.gov. Available at https://www.clinicaltrials.gov/ct2/show/NCT04431453 . 2020 Jun 01; Accessed: December 1, 2021.

Chiotos K, Hayes M, Kimberlin DW, Jones SB, James SH, Pinninti SG, et al. Multicenter interim guidance on use of antivirals for children with COVID-19/SARS-CoV-2. J Pediatric Infect Dis Soc . 2020 Sep 12. [QxMD MEDLINE Link] . [Full Text] .

Burwick RM, Yawetz S, Stephenson KE, Collier AY, Sen P, Blackburn BG, et al. Compassionate Use of Remdesivir in Pregnant Women with Severe Covid-19. Clin Infect Dis . 2020 Oct 8. [QxMD MEDLINE Link] . [Full Text] .

McCoy JA, Short WR, Srinivas SK, Levine LD, Hirshberg A. Compassionate use of remdesivir for treatment of severe coronavirus disease 2019 in pregnant women at a United States academic center. Am J Obstet Gynecol MFM . 2020 Aug. 2 (3):100164. [QxMD MEDLINE Link] . [Full Text] .

Hammond J, Leister-Tebbe H, Gardner A, and the, EPIC-HR Investigators. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med . 2022 Feb 16. [QxMD MEDLINE Link] . [Full Text] .

Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate in reducing risk of hospitalization or death. Pfizer, Inc . 2021 Dec 14. Available at https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results .

A post-exposure prophylaxis study of PF-07321332/ritonavir in adult household contacts of an individual with symptomatic COVID-19. ClinicalTrials.gov. Available at https://www.clinicaltrials.gov/ct2/show/NCT05047601 . 2021 Dec 01; Accessed: December 14, 2021.

Xie Y, Choi T, Al-Aly Z. Nirmatrelvir and the risk of post-acute sequelae of COVID-19. medRxiv . November 5, 2022. [Full Text] .

Liu J, Pan X, Zhang S, Li M, Ma K, Fan C, et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study. Lancet Reg Health West Pac . 2023 Feb 6. 100694. [QxMD MEDLINE Link] . [Full Text] .

Wong CKH, Lau KTK, Au ICH, Lau EHY, Poon LLM, Hung IFN, et al. Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study. Lancet Infect Dis . 2023 Feb 13. [QxMD MEDLINE Link] . [Full Text] .

Zheng Q, Ma P, Wang M, Cheng Y, Zhou M, Ye L, et al. Efficacy and safety of Paxlovid for COVID-19:a meta-analysis. J Infect . 2023 Jan. 86 (1):66-117. [QxMD MEDLINE Link] . [Full Text] .

Jayk Bernal A, Gomes da Silva MM, Musungaie DB, and the, MOVe-OUT Study Group. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med . 2022 Feb 10. 386:509-520. [QxMD MEDLINE Link] . [Full Text] .

Xie Y, Bowe B, Al-Aly Z. Molnupiravir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records. BMJ . 2023 Mar 7. 380:e072705. [QxMD MEDLINE Link] . [Full Text] .

Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, et al. Effectiveness of Molnupiravir in High-Risk Patients: A Propensity Score Matched Analysis. Clin Infect Dis . 2023 Feb 8. 76 (3):453-460. [QxMD MEDLINE Link] . [Full Text] .

Merck provides update on phase 3 MOVe-AHEAD trial evaluating Lagevrio (molnupiravir) for post-exposure prophylaxis for prevention of COVID-19. Merck . 2023 Feb 21. Available at https://www.merck.com/news/merck-provides-update-on-phase-3-move-ahead-trial-evaluating-lagevrio-molnupiravir-for-post-exposure-prophylaxis-for-prevention-of-covid-19/ .

Ingraham NE, Lotfi-Emran S, Thielen BK, Techar K, Morris RS, Holtan SG, et al. Immunomodulation in COVID-19. Lancet Respir Med . 2020 May 4. [QxMD MEDLINE Link] . [Full Text] .

Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN. Pharmaco-Immunomodulatory Therapy in COVID-19. Drugs . 2020 Sep. 80 (13):1267-1292. [QxMD MEDLINE Link] . [Full Text] .

Peterson JH, Paranjape NS, Grundlingh N, Priestley JL. Outcomes and Adverse Effects of Baricitinib Versus Tocilizumab in the Management of Severe COVID-19. Crit Care Med . 2023 Mar 1. 51 (3):337-346. [QxMD MEDLINE Link] . [Full Text] .

Cawcutt KA, Kalil AC. Baricitinib or Tocilizumab? Treatment of Patients Hospitalized With Severe COVID-19. Crit Care Med . 2023 Mar 1. 51 (3):413-415. [QxMD MEDLINE Link] .

Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis . 2020 Apr. 20 (4):400-402. [QxMD MEDLINE Link] . [Full Text] .

Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet . 2020 Feb 15. 395 (10223):e30-e31. [QxMD MEDLINE Link] . [Full Text] .

Stebbing J, Krishnan V, de Bono S, Ottaviani S, Casalini G, Richarson PJ, et al. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. 2020 Apr 15. [Full Text] .

Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med . 2020 Dec 11. [QxMD MEDLINE Link] . [Full Text] .

Kalil AC, Stebbing J. Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial. Lancet Respir Med . 2021 Aug 31. [QxMD MEDLINE Link] . [Full Text] .

Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med . 2021 Aug 31. [QxMD MEDLINE Link] . [Full Text] .

Lilly and Incyte’s baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation. Lilly. Available at https://investor.lilly.com/news-releases/news-release-details/lilly-and-incytes-baricitinib-reduced-deaths-among-patients . 2021 Aug 03; Accessed: December 1, 2021.

Guimarães PO, Quirk D, Furtado RH, and the STOP-COVID Trial Investigators. Tofacitinib in patients hospitalized with COVID-19 pneumonia. N Engl J Med . 2021 Jun 16. [QxMD MEDLINE Link] . [Full Text] .

Wagner JL, Veve MP, Barber KE. Using IL-6 inhibitors to treat COVID-19. ContagionLive. Available at https://www.contagionlive.com/publications/contagion/2020/august/using-il6-inhibitors-to-treat-covid19?ekey=c2NiZXJnbWFuQG5lYnJhc2thbWVkLmNvbQ . 2020 Aug 17; Accessed: December 1, 2021.

[Guideline] NIH. The COVID-19 Treatment Guidelines Panel’s Statement on the Use of Tocilizumab (and Other Interleukin-6 Inhibitors) for the Treatment of COVID-19. COVID-19 Treatment Guidelines. Available at https://www.covid19treatmentguidelines.nih.gov/immune-based-therapy/interleukin-6-inhibitors/ . 2021 Mar 05; Accessed: December 1, 2021.

Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med . 2021 Jan 7. 384 (1):20-30. [QxMD MEDLINE Link] . [Full Text] .

Rosas IO, Diaz G, Gottlieb RL, Lobo SM, Robinson P, Hunter BD, et al. Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial. Intensive Care Med . 2021 Nov. 47 (11):1258-1270. [QxMD MEDLINE Link] . [Full Text] .

REMAP-CAP Investigators., Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med . 2021 Apr 22. 384 (16):1491-1502. [QxMD MEDLINE Link] . [Full Text] .

RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet . 2021 May 1. 397 (10285):1637-1645. [QxMD MEDLINE Link] . [Full Text] .

Rosas IO, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, et al. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. N Engl J Med . 2021 Apr 22. 384 (16):1503-1516. [QxMD MEDLINE Link] . [Full Text] .

Rubin EJ, Longo DL, Baden LR. Interleukin-6 Receptor Inhibition in Covid-19 - Cooling the Inflammatory Soup. N Engl J Med . 2021 Apr 22. 384 (16):1564-1565. [QxMD MEDLINE Link] . [Full Text] .

[Guideline] NIH. Interleukin-1 Inhibitors. COVID-19 Treatment Guidelines. Available at https://www.covid19treatmentguidelines.nih.gov/immune-based-therapy/interleukin-1-inhibitors/ . 2020 Jul 17; Accessed: September 8, 2021.

[Guideline] Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. World Health Organization. Available at https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected . 2020 Mar 13; Accessed: March 24, 2020.

Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet . 2020 Feb 15. 395 (10223):473-475. [QxMD MEDLINE Link] .

[Guideline] Alhazzani W, Evans L, Alshamsi F, Møller MH, Ostermann M, Prescott HC, et al. Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update. Crit Care Med . 2021 Mar 1. 49 (3):e219-e234. [QxMD MEDLINE Link] . [Full Text] .

WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA . 2020 Sep 2. [QxMD MEDLINE Link] . [Full Text] .

Prescott HC, Rice TW. Corticosteroids in COVID-19 ARDS: Evidence and Hope During the Pandemic. JAMA . 2020 Sep 2. [QxMD MEDLINE Link] . [Full Text] .

[Guideline] WHO. Corticosteroids for COVID-19 – Living Guidance. World Health Organization. Available at https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1 . 2020 Sep 02; Accessed: December 1, 2021.

Afzali B, Noris M, Lambrecht BN, Kemper C. The state of complement in COVID-19. Nat Rev Immunol . 2022 Feb. 22 (2):77-84. [QxMD MEDLINE Link] . [Full Text] .

Carvelli J, Demaria O, Vély F, Batista L, Chouaki Benmansour N, Fares J, et al. Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis. Nature . 2020 Dec. 588 (7836):146-150. [QxMD MEDLINE Link] . [Full Text] .

Aiello S, Gastoldi S, Galbusera M, Ruggenenti P, Portalupi V, Rota S, et al. C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19. Blood Adv . 2022 Jan 8. 6 (3):866-881. [QxMD MEDLINE Link] . [Full Text] .

Vlaar APJ, Witzenrath M, van Paassen P, and the, PANAMO study group. Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med . 2022 Dec. 10 (12):1137-1146. [QxMD MEDLINE Link] . [Full Text] .

Strich JR, Tian X, Samour M, King CS, Shlobin O, Reger R, et al. Fostamatinib for the treatment of hospitalized adults with COVD-19 A randomized trial. Clin Infect Dis . 2021 Sep 1. [QxMD MEDLINE Link] . [Full Text] .

Reis G, Moreira Silva EAS, Medeiros Silva DC, and the, TOGETHER Investigators. Early Treatment with Pegylated Interferon Lambda for Covid-19. N Engl J Med . 2023 Feb 9. 388 (6):518-528. [QxMD MEDLINE Link] . [Full Text] .

Kalil AC, Mehta AK, Patterson TF, and the, ACTT-3 study group members. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med . 2021 Oct 18. [QxMD MEDLINE Link] . [Full Text] .

Schönbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?. Circulation . 2004 Jun 1. 109 (21 Suppl 1):II18-26. [QxMD MEDLINE Link] . [Full Text] .

Hariyanto TI, Kurniawan A. Statin therapy did not improved the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr . 2020 Aug 26. 14(6):1613-1615. [QxMD MEDLINE Link] . [Full Text] .

Kow CS, Hasan SS. Meta-analysis of Effect of Statins in Patients with COVID-19. Am J Cardiol . 2020 Aug 12. [QxMD MEDLINE Link] . [Full Text] .

Castiglione V, Chiriacò M, Emdin M, Taddei S, Vergaro G. Statin therapy in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother . 2020 Jul 1. 6 (4):258-259. [QxMD MEDLINE Link] . [Full Text] .

[Guideline] NIH. Covid-19 Treatment Guidelines - Adjunctive Therapy. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/adjunctive-therapy/ . 2020 Jul 17; Accessed: December 1, 2021.

Yao JS, Paguio JA, Dee EC, Tan HC, Moulick A, Milazzo C, et al. The minimal effect of zinc on the survival of hospitalized patients with Covid-19: an observational study. Chest . 2020 Jul 22. [QxMD MEDLINE Link] . [Full Text] .

Meltzer DO, Best TJ, Zhang H, Vokes T, Arora V, Solway J. Association of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test Results. JAMA Netw Open . 2020 Sep 1. 3 (9):e2019722. [QxMD MEDLINE Link] . [Full Text] .

Sahota O. Understanding vitamin D deficiency. Age Ageing . 2014 Sep. 43 (5):589-91. [QxMD MEDLINE Link] . [Full Text] .

Bishop CW, Ashfaq A, Melnick JZ, Vazquez-Escarpanter E, Fialkow JA, Strugnell SA, et al. Results from the REsCUe trial: a randomized controlled trial with extended-release calcifediol in symptomatic outpatients with COVID-19. medRXiv . 2022 Feb 05. [Full Text] .

NIH COVID-19 Treatment Guidelines Panel. Statement on the emergency use authorization of convalescent plasma for the treatment of COVID-19. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/statement-on-convalescent-plasma-eua/ . 2022 Dec 01; Accessed: February 1, 2023.

Senefeld JW, Franchini M, Mengoli C, Cruciani M, Zani M, Gorman EK, et al. COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis. JAMA Netw Open . 2023 Jan 3. 6 (1):e2250647. [QxMD MEDLINE Link] . [Full Text] .

Writing Committee for the REMAP-CAP Investigators, Estcourt LJ, Turgeon AF, McQuilten ZK, et al. Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA . 2021 Oct 4. [QxMD MEDLINE Link] .

A Study to Investigate the Prevention of COVID-19 with VYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2. ClinicalTrials.gov. Available at https://classic.clinicaltrials.gov/ct2/show/NCT06039449 . 2024 January 18; Accessed: April 1, 2024.

Levin MJ, Ustianowski A, De Wit S, and the, PROVENT Study Group. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N Engl J Med . 2022 Jun 9. 386 (23):2188-2200. [QxMD MEDLINE Link] . [Full Text] .

Young-Xu Y, Epstein L, Marconi VC, Davey V, Zwain G, Smith J, et al. Tixagevimab/cilagavimab for prevention of COVID-19 during the omicron surge: Retrospective analysis of national VA electronic data. medRxiv . 2022 May 29. [Full Text] .

Westendorf K, Žentelis S, Wang L, Foster D, Vaillancourt P, Wiggin M, et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Rep . 2022 May 17. 39 (7):110812. [QxMD MEDLINE Link] . [Full Text] .

Gupta A, Gonzalez-Rojas Y, Juarez E, and the, COMET-ICE Investigators. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med . 2021 Nov 18. 385 (21):1941-1950. [QxMD MEDLINE Link] . [Full Text] .

GSK and Vir submit emergency use authorization application to FDA for intramuscular administration of sotrovimab for the early treatment of COVID-19. GlaxoSmithKline . 2022 Jan 13. Available at https://us.gsk.com/en-us/media/press-releases/gsk-and-vir-submit-emergency-use-authorization-application-to-fda-for-intramuscular-administration-of-sotrovimab-for-the-early-treatment-of-covid-19/ .

O'Brien MP, Forleo-Neto E, Musser BJ, and the, Covid-19 Phase 3 Prevention Trial Team. Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19. N Engl J Med . 2021 Aug 4. [QxMD MEDLINE Link] . [Full Text] .

Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med . 2020 Dec 17. [QxMD MEDLINE Link] . [Full Text] .

RECOVERY Collaborative Group, Horby PW, Mafham M, Peto L, et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomized, controlled, open-label, platform trial. medRxiv . 2021 Jun 16. [Full Text] .

Dougan M, Nirula A, Azizad M, and the, BLAZE-1 Investigators. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. N Engl J Med . 2021 Oct 7. 385 (15):1382-1392. [QxMD MEDLINE Link] . [Full Text] .

Cohen MS, Nirula A, Mulligan MJ, and the, BLAZE-2 Investigators. Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial. JAMA . 2021 Jul 6. 326 (1):46-55. [QxMD MEDLINE Link] . [Full Text] .

Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med . 2020 May 21. 382 (21):1969-1973. [QxMD MEDLINE Link] . [Full Text] .

Koirala A, Joo YJ, Khatami A, Chiu C, Britton PN. Vaccines for COVID-19: The current state of play. Paediatr Respir Rev . 2020 Sep. 35:43-49. [QxMD MEDLINE Link] . [Full Text] .

Iba T, Levy JH, Levi M, Connors JM, Thachil J. Coagulopathy of Coronavirus Disease 2019. Crit Care Med . 2020 Sep. 48 (9):1358-1364. [QxMD MEDLINE Link] . [Full Text] .

Katneni UK, Alexaki A, Hunt RC, Schiller T, DiCuccio M, Buehler PW, et al. Coagulopathy and Thrombosis as a Result of Severe COVID-19 Infection: A Microvascular Focus. Thromb Haemost . 2020 Aug 24. [QxMD MEDLINE Link] . [Full Text] .

Ferguson J, Volk S, Vondracek T, Flanigan J, Chernaik A. Empiric therapeutic anticoagulation and mortality in critically ill patients with respiratory failure from SARS-CoV-2: A retrospective cohort study. J Clin Pharmacol . 2020 Sep 3. [QxMD MEDLINE Link] . [Full Text] .

Paranjpe I, Fuster V, Lala A, Russak AJ, Glicksberg BS, Levin MA, et al. Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19. J Am Coll Cardiol . 2020 Jul 7. 76 (1):122-124. [QxMD MEDLINE Link] . [Full Text] .

NIH ACTIV-4B COVID-19 outpatient thrombosis prevention trial ends early. Brigham Health . 2021 Jun 22. Available at https://www.brighamandwomens.org/about-bwh/newsroom/press-releases-detail?id=3925 .

REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, Goligher EC, Bradbury CA, McVerry BJ, et al. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. N Engl J Med . 2021 Aug 4. [QxMD MEDLINE Link] . [Full Text] .

ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Lawler PR, Goligher EC, Berger JS, et al. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med . 2021 Aug 4. [QxMD MEDLINE Link] . [Full Text] .

Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19 (ASPEN). ClinicalTrials.gov. Available at https://www.clinicaltrials.gov/ct2/show/NCT04655586 . 2021 Nov 03; Accessed: December 6, 2021.

Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature . 2020 Mar. 579 (7798):270-273. [QxMD MEDLINE Link] . [Full Text] .

Lopes RD, Macedo AVS, de Barros E Silva PGM, Moll-Bernardes RJ, Feldman A, D'Andréa Saba Arruda G, et al. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial. Am Heart J . 2020 Aug. 226:49-59. [QxMD MEDLINE Link] . [Full Text] .

Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease. Circulation . 2020 Mar 21. [QxMD MEDLINE Link] . [Full Text] .

Fang L, Karakiulakis G, Roth M. Correction to Lancet Respir Med 2020; 8: e21. Lancet Respir Med . 2020 Jun. 8 (6):e54. [QxMD MEDLINE Link] . [Full Text] .

Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med . 2005 Aug. 11 (8):875-9. [QxMD MEDLINE Link] . [Full Text] .

Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon S. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med . 2020 March 30. [QxMD MEDLINE Link] . [Full Text] .

Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension . 2004 May. 43 (5):970-6. [QxMD MEDLINE Link] . [Full Text] .

Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation . 2005 May 24. 111 (20):2605-10. [QxMD MEDLINE Link] . [Full Text] .

Klimas J, Olvedy M, Ochodnicka-Mackovicova K, Kruzliak P, Cacanyiova S, Kristek F, et al. Perinatally administered losartan augments renal ACE2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats. J Cell Mol Med . 2015 Aug. 19 (8):1965-74. [QxMD MEDLINE Link] . [Full Text] .

Walters TE, Kalman JM, Patel SK, Mearns M, Velkoska E, Burrell LM. Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling. Europace . 2017 Aug 1. 19 (8):1280-1287. [QxMD MEDLINE Link] . [Full Text] .

Burchill LJ, Velkoska E, Dean RG, Griggs K, Patel SK, Burrell LM. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions. Clin Sci (Lond) . 2012 Dec. 123 (11):649-58. [QxMD MEDLINE Link] .

Bozkurt B, Kovacs R, Harrington B. Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19. J Card Fail . 2020 May. 26 (5):370. [QxMD MEDLINE Link] . [Full Text] .

Sama IE, Ravera A, Santema BT, van Goor H, Ter Maaten JM, Cleland JGF, et al. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. Eur Heart J . 2020 May 14. 41 (19):1810-1817. [QxMD MEDLINE Link] . [Full Text] .

Baral R, Tsampasian V, Debski M, Moran B, Garg P, Clark A, et al. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. JAMA Netw Open . 2021 Mar 1. 4 (3):e213594. [QxMD MEDLINE Link] . [Full Text] .

Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax . 2015 Oct. 70 (10):984-9. [QxMD MEDLINE Link] . [Full Text] .

Drucker DJ. Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications. Endocr Rev . 2020 Apr 15. [QxMD MEDLINE Link] . [Full Text] .

Muniyappa R, Gubbi S. COVID-19 Pandemic, Corona Viruses, and Diabetes Mellitus. Am J Physiol Endocrinol Metab . 2020 Mar 31. [QxMD MEDLINE Link] . [Full Text] .

DPP4 dipeptidyl peptidase 4. National Center for Biotechnology Information (NCBI). Available at https://www.ncbi.nlm.nih.gov/gene/1803 . 2020 Apr 20; Accessed: 2020 Apr 21.

RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomized, controlled, open-label, platform trial. The Lancet . 2020 Oct 05. [Full Text] .

Momekov G, Momekova D. Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens. Biotechnology & Biotechnological Equipment. 2020 . 2020. 34(1):469-74. [Full Text] .

Chaccour C, Hammann F, Ramón-García S, Rabinovich NR. Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency. Am J Trop Med Hyg . 2020 Apr 16. [QxMD MEDLINE Link] . [Full Text] .

López-Medina E, López P, Hurtado IC, Dávalos DM, Ramirez O, Martínez E, et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial. JAMA . 2021 Apr 13. 325 (14):1426-1435. [QxMD MEDLINE Link] . [Full Text] .

Lim SCL, Hor CP, Tay KH, and the, I-TECH Study Group. Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH Randomized Clinical Trial. JAMA Intern Med . 2022 Feb 18. [QxMD MEDLINE Link] . [Full Text] .

Reis G, Silva EASM, Silva DCM, and the, TOGETHER Investigators. Effect of Early Treatment with Ivermectin among Patients with Covid-19. N Engl J Med . 2022 May 5. 386 (18):1721-1731. [QxMD MEDLINE Link] . [Full Text] .

Naggie S, Boulware DR, Lindsell CJ, for the, Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-6) Study Group and Investigators. Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA . 2022 Oct 25. 328 (16):1595-1603. [QxMD MEDLINE Link] . [Full Text] .

Naggie S, Boulware DR, Lindsell CJ, for the, Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators. Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial. JAMA . 2023 Feb 20. [QxMD MEDLINE Link] . [Full Text] .

Bramante CT, Huling JD, Tignanelli CJ, for the COVID-OUT Trial Team. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. N Eng J Med . 2022. 387:599-610. [Full Text] .

Reis G, Dos Santos Moreira-Silva EA, Silva DCM, and the, TOGETHER investigators. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health . 2022 Jan. 10 (1):e42-e51. [QxMD MEDLINE Link] . [Full Text] .

McCarthy MW, Naggie S, Boulware DR, and the, Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators. Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA . 2023 Jan 24. 329 (4):296-305. [QxMD MEDLINE Link] .

Golan Y, Campos JAS, Woolson R, Cilla D, Hanabergh R, Gonzales-Rojas Y, et al. Favipiravir in Patients With Early Mild-to-moderate Coronavirus Disease 2019 (COVID-19): A Randomized Controlled Trial. Clin Infect Dis . 2023 Feb 8. 76 (3):e10-e17. [QxMD MEDLINE Link] . [Full Text] .

Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med . 2012 May 17. 366 (20):1881-90. [QxMD MEDLINE Link] . [Full Text] .

Simpson TF, Kovacs RJ, Stecker EC. Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19. American College of Cardiology; Cardiology Magazine. Available at https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19 . 2020 Mar 29; Accessed: April 1, 2020.

[Guideline] Roden DM, Harrington RA, Poppas A, Russo AM. Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment. Circulation . 2020 Apr 8. [QxMD MEDLINE Link] . [Full Text] .

[Guideline] Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. Urgent guidance for navigating and circumventing the QTc prolonging and torsadogenic potential of possible pharmacotherapies for COVID-19. Mayo Clin Proc . 2020 Apr 07. [Full Text] .

Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol . 2020 May 1. [QxMD MEDLINE Link] . [Full Text] .

Chorin E, Dai M, Shulman E, Wadhwani L, et al. The QT Interval in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine/Azithromycin. medRxiv . 2020 Apr 03. [Full Text] .

Borba M, de Almeida Val F, Sampaio VS, Alexandre MA, Melo GC, Brito M, et al. Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study). MedRxiv . 2020 Apr 11. [Full Text] .

Lane JCE, Weaver J, Kostka K, Duarte-Salles T, Abrahao MTF, Alghoul H, et al. Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study. medRxiv . 2020 Apr 10. [Full Text] .

Supady A, Weber E, Rieder M, Lother A, Niklaus T, Zahn T, et al. Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial. Lancet Respir Med . 2021 Jul. 9 (7):755-762. [QxMD MEDLINE Link] . [Full Text] .

Matson J, Lange P, Honore PM, Chung KK. Adverse outcomes with extracorporeal adsorbent blood treatments in toxic systemic inflammation: a perspective on possible mechanisms. Ann Intensive Care . 2022 Nov 12. 12 (1):105. [QxMD MEDLINE Link] . [Full Text] .

Zhang Q, et al. Cellular nanosponges inhibit SARS-CoV-2 infectivity. Nano Lett . 2020 Jun 17. [QxMD MEDLINE Link] . [Full Text] .

[Guideline] Centers for Disease Control and Prevention. Interim guidelines for collecting, handling, and testing clinical specimens from persons for coronavirus disease 2019 (COVID-19). CDC. Available at https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html . 2020 Nov 05; Accessed: November 16, 2020.

[Guideline] Center for Clinical Standards and Quality/Quality, Safety & Oversight Group. Guidance for Infection Control and Prevention Concerning Coronavirus Disease (COVID-19): FAQs and Considerations for Patient Triage, Placement and Hospital Discharge. Available at https://www.cms.gov/files/document/qso-20-13-hospitalspdf.pdf-2 . March 4, 2020; Accessed: March 4, 2020.

Puopolo KM, Hudak ML, Kimberlin DW, Cummings J. Management of Infants Born to Mothers with COVID-19. American Academy of Pediatrics. Available at https://downloads.aap.org/AAP/PDF/COVID%2019%20Initial%20Newborn%20Guidance.pdf . April 2, 2020; Accessed: April 3, 2020.

[Guideline] AAP. FAQs: Management of Infants Born to Mothers with Suspected or Confirmed COVID-19. American Academy of Pediatrics. Available at https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/faqs-management-of-infants-born-to-covid-19-mothers/ . May 21, 2020; Accessed: May 27, 2020.

[Guideline] COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/ . 2021 Mar 05; Accessed: March 12, 2021.

[Guideline] Moores LK, Tritschler T, Brosnahan S, Carrier M, Collen JF, Doerschug K, et al. Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST Guideline and Expert Panel Report. Chest . 2020 Jun 2. [QxMD MEDLINE Link] . [Full Text] .

[Guideline] Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost . 2020 May. 18 (5):1023-1026. [QxMD MEDLINE Link] . [Full Text] .

[Guideline] COVID-19 Treatment Guidelines Panel. Antithrombotic Therapy in Patients with COVID-19. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/antithrombotic-therapy/ . 2021 Feb 11; Accessed: June 28, 2021.

World Health Organization. Roadmap to improve and ensure good indoor ventilation in COVID-19 context (1 March 2021). World Health Organization. Available at https://www.who.int/publications/i/item/9789240021280 . March 1, 2021; Accessed: February 20, 2024.

Lim EHT, Vlaar APJ, Bos LDJ, and the, Amsterdam UMC COVID-19 Biobank Investigators. Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the  phase 2 PANAMO trial. Respir Res . 2022 Dec 24. 23 (1):375. [QxMD MEDLINE Link] . [Full Text] .

Management Strategies in Children and Adolescents with Mild to Moderate COVID-19. American Academy of Pediatri cs. Available at https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/outpatient-covid-19-management-strategies-in-children-and-adolescents/ . Updated February 8, 2023; Accessed: March 6, 2024.

Huang YH, Kuo HC. Kawasaki Disease, MIS-C and COVID-19. Children (Basel) . 2023 Sep 22. 10 (10): [QxMD MEDLINE Link] . [Full Text] .

Simbar M, Nazarpour S, Sheidaei A. Evaluation of pregnancy outcomes in mothers with COVID-19 infection: a systematic review and meta-analysis. J Obstet Gynaecol . 2023 Dec. 43 (1):2162867. [QxMD MEDLINE Link] .

Rojas-Suarez J, Miranda J. Coronavirus Disease-2019 in Pregnancy. Clin Chest Med . 2023 Jun. 44 (2):373-384. [QxMD MEDLINE Link] .

He YF, Liu JQ, Hu XD, Li HM, Wu N, Wang J, et al. Breastfeeding vs. breast milk transmission during COVID-19 pandemic, which is more important?. Front Pediatr . 2023. 11:1253333. [QxMD MEDLINE Link] . [Full Text] .

Weiss A, Donnachie E, Beyerlein A, Ziegler AG, Bonifacio E. Type 1 Diabetes Incidence and Risk in Children With a Diagnosis of COVID-19. JAMA . 2023 Jun 20. 329 (23):2089-2091. [QxMD MEDLINE Link] .

Lippi G, Sanchis-Gomar F, Henry BM. COVID-19 and its long-term sequelae: what do we know in 2023?. Pol Arch Intern Med . 2023. 133: [Full Text] .

Brolly J, Chadwick DR. COVID-19 infection in people living with HIV. Br Med Bull . 2023 Sep 12. 147 (1):20-30. [QxMD MEDLINE Link] . [Full Text] .

• The heart is normal in size. There are diffuse, patchy opacities throughout both lungs, which may represent multifocal viral/bacterial pneumonia versus pulmonary edema. These opacities are particularly confluent along the periphery of the right lung. There is left midlung platelike atelectasis. Obscuration of the left costophrenic angle may represent consolidation versus a pleural effusion with atelectasis. There is no pneumothorax.
• The heart is normal in size. There are bilateral hazy opacities, with lower lobe predominance. These findings are consistent with multifocal/viral pneumonia. No pleural effusion or pneumothorax are seen.
• The heart is normal in size. Patchy opacities are seen throughout the lung fields. Patchy areas of consolidation at the right lung base partially silhouettes the right diaphragm. There is no effusion or pneumothorax. Degenerative changes of the thoracic spine are noted.
• The same patient as above 10 days later.
• The trachea is in midline. The cardiomediastinal silhouette is normal in size. There are diffuse hazy reticulonodular opacities in both lungs. Differential diagnoses include viral pneumonia, multifocal bacterial pneumonia or ARDS. There is no pleural effusion or pneumothorax.
• Axial chest CT demonstrates patchy ground-glass opacities with peripheral distribution.
• Coronal reconstruction chest CT of the same patient above, showing patchy ground-glass opacities.
• Axial chest CT shows bilateral patchy consolidations (arrows), some with peripheral ground-glass opacity. Findings are in peripheral and subpleural distribution.
• Table 1. SARS-CoV-2 Monoclonal Antibodies – inactive EUAs

Contributor Information and Disclosures

David J Cennimo, MD, FAAP, FACP, FIDSA, AAHIVS Associate Professor of Medicine and Pediatrics, Adult and Pediatric Infectious Diseases, Rutgers New Jersey Medical School David J Cennimo, MD, FAAP, FACP, FIDSA, AAHIVS is a member of the following medical societies: American Academy of HIV Medicine , American Academy of Pediatrics , American College of Physicians , American Medical Association , HIV Medicine Association , Infectious Diseases Society of America , Medical Society of New Jersey , Pediatric Infectious Diseases Society Disclosure: Nothing to disclose.

Scott J Bergman, PharmD, FCCP, FIDSA, BCPS, BCIDP Antimicrobial Stewardship Program Coordinator, Infectious Diseases Pharmacy Residency Program Director, Department of Pharmaceutical and Nutrition Care, Division of Infectious Diseases, Nebraska Medicine; Clinical Associate Professor, Department of Pharmacy Practice, College of Pharmacy, University of Nebraska Medical Center Scott J Bergman, PharmD, FCCP, FIDSA, BCPS, BCIDP is a member of the following medical societies: American Association of Colleges of Pharmacy , American College of Clinical Pharmacy , American Pharmacists Association , American Society for Microbiology , American Society of Health-System Pharmacists , Infectious Diseases Society of America , Society of Infectious Diseases Pharmacists Disclosure: Received research grant from: Merck & Co., Inc.

Keith M Olsen, PharmD, FCCP, FCCM Dean and Professor, College of Pharmacy, University of Nebraska Medical Center Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference Disclosure: Nothing to disclose.

Michael Stuart Bronze, MD David Ross Boyd Professor and Chairman, Department of Medicine, Stewart G Wolf Endowed Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center; Master of the American College of Physicians; Fellow, Infectious Diseases Society of America; Fellow of the Royal College of Physicians, London Michael Stuart Bronze, MD is a member of the following medical societies: Alpha Omega Alpha , American College of Physicians , American Medical Association , Association of Professors of Medicine , Infectious Diseases Society of America , Oklahoma State Medical Association , Southern Society for Clinical Investigation Disclosure: Nothing to disclose.

Molly Marie Miller, PharmD Clinical Infectious Diseases Pharmacist Practitioner, Nebraska Medicine Molly Marie Miller, PharmD is a member of the following medical societies: Society of Infectious Diseases Pharmacists Disclosure: Nothing to disclose.

What would you like to print?

• Print this section
• Print the entire contents of
• Print the entire contents of article

• COVID-19 Variants
• COVID-19 Pulmonary Management
• COVID-19 Reinfections
• Long Coronavirus 2019 (COVID-19)
• Symptoms and Management of Coronavirus Disease 2019 (COVID-19) FAQ
• Coronavirus Disease 2019 (COVID-19)
• Diagnostics for Coronavirus Disease 2019 (COVID-19) Patients
• Picture of COVID-19 in Europe Is Complex
• Global Consensus Reached on COVID-19 Vaccine Updates
• Beyond COVID-19: building Europe’s pandemic preparedness

• Drug Interaction Checker
• Pill Identifier
• Calculators

• 2010comirnaty-covid-19-vaccine-mRNA-pfizer-4000140Drugs Drugs COVID-19 vaccine, mRNA-Pfizer

• 2010covid-19-vaccine-adjuvanted-novavax-4000146Drugs Drugs COVID-19 vaccine, adjuvanted-Novavax
• 2010spikevax-covid-19-vaccine-mRNA-moderna-4000149Drugs Drugs COVID-19 vaccine, mRNA-Moderna

• SUGGESTED TOPICS
• The Magazine
• Newsletters
• Managing Yourself
• Managing Teams
• Work-life Balance
• The Big Idea
• Data & Visuals
• Reading Lists
• Case Selections
• HBR Learning
• Topic Feeds
• Account Settings
• Email Preferences

How to Make a “Good” Presentation “Great”

• Guy Kawasaki

Remember: Less is more.

A strong presentation is so much more than information pasted onto a series of slides with fancy backgrounds. Whether you’re pitching an idea, reporting market research, or sharing something else, a great presentation can give you a competitive advantage, and be a powerful tool when aiming to persuade, educate, or inspire others. Here are some unique elements that make a presentation stand out.

• Fonts: Sans Serif fonts such as Helvetica or Arial are preferred for their clean lines, which make them easy to digest at various sizes and distances. Limit the number of font styles to two: one for headings and another for body text, to avoid visual confusion or distractions.
• Colors: Colors can evoke emotions and highlight critical points, but their overuse can lead to a cluttered and confusing presentation. A limited palette of two to three main colors, complemented by a simple background, can help you draw attention to key elements without overwhelming the audience.
• Pictures: Pictures can communicate complex ideas quickly and memorably but choosing the right images is key. Images or pictures should be big (perhaps 20-25% of the page), bold, and have a clear purpose that complements the slide’s text.
• Layout: Don’t overcrowd your slides with too much information. When in doubt, adhere to the principle of simplicity, and aim for a clean and uncluttered layout with plenty of white space around text and images. Think phrases and bullets, not sentences.

As an intern or early career professional, chances are that you’ll be tasked with making or giving a presentation in the near future. Whether you’re pitching an idea, reporting market research, or sharing something else, a great presentation can give you a competitive advantage, and be a powerful tool when aiming to persuade, educate, or inspire others.

• Guy Kawasaki is the chief evangelist at Canva and was the former chief evangelist at Apple. Guy is the author of 16 books including Think Remarkable : 9 Paths to Transform Your Life and Make a Difference.

Partner Center

NASP: The National Association of School Psychologists

NASP Annual Convention

In this section.

• Session Handouts
• Convention FAQs
• Future Conventions
• Past Conventions

Important Dates

Space request submission system opens, space request submission system closes, notification of accepted presentations, registration opens (10:00 a.m. et), early registration deadline.

Mark Your Calendar for Seattle

Don't miss the largest annual convention for school psychologists.

Connect with over 5,000 peers in the field and expand your expertise with over 1,200 professional development sessions. The convention will take place from February 18–21, 2025, and be held at the Seattle Convention Center Summit.

Registration will open Tuesday, October 1. Not a NASP member? Join or renew  ahead of time to register for the in-person convention at a discounted price . Only through November 20, the combined cost of membership and the discounted registration rate will be LESS THAN the nonmember registration fee! 

Would you like to present a session at NASP 2025?

NASP is seeking presentations that will appeal to seasoned practitioners and assist them in delivering the highest quality, evidence-based practices in school.

To review the types of presentations and application process, visit the Call for Presentation Proposals webpage.

Looking for NASP 2024 Materials?

Recordings of seven Documented Sessions are now available on demand! Through June 30, 2024,  get 15% off 4–5 sessions and 20% off 6–7 sessions .

Convention attendees may review and download session handouts  online ! 

Convention Cancellation Policy: Individuals who submit written requests for refunds on or before January 10, 2024, will receive a full refund, minus a $50 administrative fee, approximately 4 weeks after the convention. Individuals submitting registration fee refund requests after January 10, 2024, may send an email to [email protected] or a letter addressed to the Meetings and Conventions Department at NASP Headquarters no later than 30 days after the convention. Please include any available documentation appropriate to support the late refund request. Refund requests will be considered on a case-by-case basis after the convention. Individuals who submit late cancellation refund requests will receive responses approximately 4 weeks after the convention.

out the various types of sessions that will be offered at convention? Utilize the complete list of sessions  to identify the sessions that align with your interests and start building your personalized schedule.

Not a NASP member? Join or renew  to register for the in-person convention at a discounted price . Only through November 15, the combined cost of membership and the discounted registration rate is LESS THAN the nonmember registration fee! 

COVID-19 Precautions

The 2023 NASP Annual Convention in Boston is proceeding as a live event, with the expectation that all individuals on do their part to stop the spread of the COVID-19 virus. NASP is putting preventative measures in place and all individuals who attend the convention should be fully vaccinated. If you have not been vaccinated, you should not attend the convention in person. Wearing a mask will be required in all event spaces, except when eating or drinking, for the entirety of the event. Additional preventative practices, such as social distancing should be expected onsite. The convention center and hotel properties have regular cleaning protocols in place and provide hand sanitizing stations.

NASP will continue to monitor the COVID-19 pandemic and federal, state, and local guidance. Please visit this section of the NASP website for additional information and updates.

Registration Information Now Available Online

Registration opens October 1, and information about registration deadlines and fees is now available online . Plan to register by November 3 to save $50 with the early registration rate and be entered for a chance to win a $500 Visa gift card. Additionally, if you are interested in registering for Boston Express—the entirely virtual component of next year's annual convention, which is a package of eight 80-minute live-streamed Documented Sessions—instead of registering for the in-person convention, plan to register by January 19 to save $50. Start planning your trip today!

Boston Express Virtual Package

If for some reason you are unable to attend next year's in-person convention, be sure to register for our Boston Express Virtual Package. This is an entirely virtual package of eight 80-minute live-streamed Documented Sessions, all of which are close-captioned and include live chats. Watch all sessions in real time to earn 10 hours of Category A CPD credit with these fantastic sessions given by leading experts in the field on topics critical to school psychologists. Plan to register by January 19 to save $50 .

Submit an Event Space Request

The NASP 2022 Annual Convention Space Request System is closed. All requests for meeting space were due no later than Wednesday, September 8, 2021, at midnight EDT . 

Please read our land acknowledgement as we recognize that the land on which we will gather for the NASP 2023 Annual Convention in the city of Denver and surrounding area is the traditional territory of the Núu-agha-tuvu-pu (Ute), Tséstho’e (Cheyenne), Ndé Kónitsąąíí Gokíyaa (Lipan Apache), and hinono’eino’ biito’owu’ (Arapaho) Peoples.

Session Handouts, Keynote, and Recordings

If you’re missing handouts from a particular session or need to download another copy, search by session number below. You can also view a recording of the keynote address and president’s remarks, or preorder a Session Recording Package to earn documented CPD and watch select sessions on-the-go.

recording of the keynote address and president’s remarks, or preorder a Session Recording Package to earn documented CPD and watch select sessions on-the-go.

The NASP 2023 Annual Convention is proceeding as a live event with the expectation that all individuals will do their part to help stop the spread of the COVID-19 Virus. All individuals who attend the convention should be fully vaccinated. Individuals who have not been vaccinated should not come to the NASP convention! At this time, masks are encouraged but not required.

The convention center and hotel properties have regular cleaning protocols in place and provide hand sanitizing stations. Certain preventative practices also may be necessary on site. Such precautions, if needed, will be announced closer to the convention dates.

NASP will continue to monitor the COVID-19 pandemic and federal, state, and local guidance. Please visit the Convention section of the NASP website, www.nasponline.org , for additional information and updates.

• Arts and Culture
• Discover Clayton
• Resident Information
• Useful Resources
• Clayton County Strategic Plan
• Veteran of the Month Program
• County Directory
• County Jobs
• Coronavirus Education/Information
• Digital Equity
• UGA Cooperative Extension
• Jury Division
• Parks and Recreation
• Payment Information
• Permits and Licenses
• Property Taxes
• Public Safety
• Spivey Splash
• Vehicle Tag Registration
• Voting & Elections
• Chamber of Commerce
• Clayton Vendor Access Portal
• County Maps
• Bids & RFPs
• Permits & Licenses
• Building Inspections
• Building Permits
• Business Licenses
• Development Authority
• Economic Development
• Film Clayton
• Find My Zoning
• Zoning Fees
• Comprehensive Transportation Plan (CTP)
• Constituent Services
• County Boards
• Community Improvement District Feasibility Study
• Office of Communications
• Office of Resilience and Sustainability/Emergency Management
• Mosquito Spraying
• C-VAP (Clayton Vendor Access Portal) Vendor Self Service
• Minority and Women-owned Business Enterprise (MWBE)
• Small Local Business Enterprise Program
• Community Development
• Corrections Department
• Clerk of Magistrate Court
• Clerk of State Court
• Clerk of Superior Court
• Court Administrator
• Public Defender’s Office
• Superior Court
• State Court
• Magistrate Court
• Juvenile Court
• Probate Court
• District Attorney
• Elections and Registration
• Fire & Emergency Services
• Human Resources
• Information Technology
• Internal Audit
• Sheriff’s Office
• Solicitor General
• Tax Assessor
• Tax Commissioner
• Transportation and Development

Meet Your Commissioners

• Find My Elected Officials
• Building Permit
• Marriage License
• Notary Public
• Public Records and Forms
• Special Events Permit
• Weapons Permit
• Channel 23/99
• Social Media
• Traffic Citations
• Vehicle Tag Renewal
• Report a Concern
• Submit a Crime Tip
• For Recreation Activities
• As a Vendor
• Schedule an Inspection
• Board of Commissioner Meetings
• SPLOST Projects

« All Events

Clayton Performance Review FY 2024 – Quarter 4 Department Presentations

July 23 @ 9:00 am - 11:00 pm.

One event on July 24, 2024 at 9:00 am

  For Immediate Release

June 21, 2024  

Clayton Performance Review  

FY 2024 – Quarter 4  

Department Presentations  

(Clayton County, GA) –The Clayton County operational departments present quarterly Clayton Performance Reviews (CPR) at the Board of Commissioners Boardroom, 112 Smith Street, Jonesboro, GA 30236, on Tues., July 23, 2024 and Wed., July, 24, 2024. The presentations begin at 9 a.m. each day.  

The purpose is to keep the public informed and engaged on the strategic plan, goals, and accomplishments. Each department will discuss their goals, successes, and challenges.  

The meeting will also be accessible via live-stream at www.claytoncountyga.gov . Citizens and county employees are invited to attend or watch online.  

For more information, access www.claytoncountyga.gov or call 770.477.3208.  

• Google Calendar
• Outlook 365
• Outlook Live

Related Events

2nd Annual Backpack Bash

Senior Adult Days at Spivey Splash Water Park

One event on August 26, 2024 at 11:00 am

• Credit cards
• View all credit cards
• Banking guide
• Loans guide
• Insurance guide
• Personal finance
• View all personal finance
• Small business
• Small business guide
• View all taxes

You’re our first priority. Every time.

We believe everyone should be able to make financial decisions with confidence. And while our site doesn’t feature every company or financial product available on the market, we’re proud that the guidance we offer, the information we provide and the tools we create are objective, independent, straightforward — and free.

So how do we make money? Our partners compensate us. This may influence which products we review and write about (and where those products appear on the site), but it in no way affects our recommendations or advice, which are grounded in thousands of hours of research. Our partners cannot pay us to guarantee favorable reviews of their products or services. Here is a list of our partners .

How Timeshare Presentations Earn Me Cheap Travel

Craig Joseph is a NerdWallet lead writer and credit cards expert. He has degrees in geology from West Virginia University and oceanography from Oregon State University and has published in academic journals, newspapers and blogs. Craig is passionate about personal finance and wants to enhance the financial literacy of everyone he meets. He'll probably also try to convince you why rocks are cool.

Giselle M. Cancio is an editor for the travel rewards team at NerdWallet. She has traveled to over 30 states and 20 countries, redeeming points and miles for almost a decade. She has over eight years of experience in journalism and content development across many topics.

She has juggled many roles in her career: writer, editor, social media manager, producer, on-camera host, videographer and photographer. She has been published in several media outlets and was selected to report from the 2016 Summer Olympics in Rio de Janeiro.

She frequents national parks and is on her way to checking all 30 Major League Baseball parks off her list. When she's not on a plane or planning her next trip, she's crafting, reading, playing board games, watching sports or trying new recipes.

She is based in Miami.

Many or all of the products featured here are from our partners who compensate us. This influences which products we write about and where and how the product appears on a page. However, this does not influence our evaluations. Our opinions are our own. Here is a list of our partners and here's how we make money .

The most avid travel hackers often shoot me a skeptical glare when I utter the words “ timeshare presentation ” as a way to get discounted hotel stays and piles of points to use toward future travel.

The deal is pretty simple: receive a heavily discounted hotel or resort stay and other perks in exchange for attending a timeshare presentation — better known as a sales pitch.

The last email offer I received was in March 2023 from Hilton Grand Vacations. It dangled a three-night stay in Las Vegas plus 50,000 Hilton Honors points in exchange for $149 and sitting through a 90-minute talk.

Having attended four timeshare presentations over the last decade, I find that the discounted hotel stay and extra perks — like hotel points and discounted spa treatments or amusement park tickets — are worth my time. All you have to do is attend the presentation and say “no” (sometimes several times) if the timeshare is not right for you.

Here’s how to get nearly free vacations with timeshare presentations.

Determine the value of the promotion, then negotiate

I've successfully negotiated the terms of a timeshare presentation in the past, so I called Hilton to see if it could sweeten the deal with upgrades like more travel rewards points or food and beverage credits.

After reviewing the terms of my promotion — and with some very polite back and forth — I requested an increase to 100,000 points and a waiver on the additional resort fees of $34 per night. After a long wait, the sales representative’s supervisor approved the deal if I accepted it on the spot, which I did.

According to NerdWallet’s valuation , Hilton points are generally worth about 0.5 cent each , giving the 100,000 points an approximate value of $500. The nightly room rate over my travel dates was $249, plus $34 per night in resort fees. That gives this deal a value of over $1,300 in exchange for 90-minutes of my time and the $149 I paid for the package.

Understand the restrictions and limitations

Certain hotels require attending the presentation with a spouse, while others may have specific income requirements. Ask about blackout dates, package expiration dates and any other hidden fees (like those pesky resort fees).

For Hilton, I had to verbally confirm my income was above a certain threshold and attest that I hadn’t participated in another Hilton-based timeshare presentation over the past six months.

Once I purchased the package, Hilton gave me 12 months to use it. After my reservation in Las Vegas was booked, Hilton assigned a set date and time for the timeshare presentation. If you miss it, the company can charge the full cash rate for the stay and revoke any perks offered.

Also be aware that you won't earn hotel points or elite night credits with the host brand for the promotional stay.

Know what to expect at the sales pitch

The pitch usually starts with an introduction to your salesperson and a general video or presentation about the company’s timeshare program. You’ll then be whisked away to an office, where the salesperson asks about your finances and travel habits. You’ll be introduced to a rubric of costs to stay at different tiers of properties — costs that may fluctuate seasonally or during periods of high demand.

Many timeshare companies, even Disney , have transitioned to a points-based system, where you buy points used to make reservations after you’re an “owner,” but be aware these points are independent of the chain’s loyalty program.

Once the salesperson estimates the cost required to live your best timeshare life, they’ll take you on a tour of a model property. You’ll then return to the office and be introduced to the “closer” — the person who ran the numbers and tries to pressure you into signing.

The sales professionals will tug at your emotions with aspirational travel fantasies while making you feel like family. Remember, they are incentivized by commissions to make you buy a timeshare through signing a contract that can last the rest of your life.

Timing the pitch using my phone allowed me to politely tell the salesperson their time was up once the required duration under the promotion elapsed (usually 90 to 120 minutes).

Be in the 'no'

Timeshares are big business, with $10.6 billion in domestic sales in 2023, according to a 2024 study by the American Resort Development Association (ARDA), a trade association for the timeshare industry. For comparison, that’s similar to the annual revenue of Major League Baseball in 2023.

Hospitality companies wouldn’t offer these lucrative promotions unless enough people were buying what they’re selling.

Jason Gamel, president and CEO of ARDA, says that approximately 2 in 10 people decide to buy after a sales presentation. And that purchase, of course, comes with a financial commitment. The average purchase transaction was $24,170 in 2023, according to the ARDA study, with average annual interest rates near 15%.

This amount covers the initial cost to join the timeshare and the financing of the balance but does not include ongoing costs such as membership dues, maintenance fees or other required resort operation expenses.

If you’re not in the market for a timeshare, no sales pitch should persuade you to get one. Before the pitch, think (or talk) through the process of saying “no,” and if you have a spouse who'll be attending, include them in the conversation.

Later, if you change your mind and decide to sign a contract, a state’s rescission laws could allow the contract to be canceled within a certain window after signing — usually between five and 10 business days.

“I think that’s important because it does help people evaluate whether they’re making the right decision for them, and it gives them a very easy way to say no after everything is said and done," says Gamel.

Simply pack up and go

Despite skepticism from my travel-hacking cohorts, timeshare promotions allow me to save money on travel now and earn rewards to use for free travel in the future. The process won’t be for everyone, but if you’re willing to sacrifice a couple of hours and know the power of saying “no,” it could do the same for you.

How to maximize your rewards

You want a travel credit card that prioritizes what’s important to you. Here are some of the best travel credit cards of 2024 :

Flexibility, point transfers and a large bonus: Chase Sapphire Preferred® Card

No annual fee: Bank of America® Travel Rewards credit card

Flat-rate travel rewards: Capital One Venture Rewards Credit Card

Bonus travel rewards and high-end perks: Chase Sapphire Reserve®

Luxury perks: The Platinum Card® from American Express

Business travelers: Ink Business Preferred® Credit Card

on Citibank's application

1%-5% Earn 5% cash back on purchases in your top eligible spend category each billing cycle, up to the first $500 spent, 1% cash back thereafter. Also, earn unlimited 1% cash back on all other purchases.

$200 Earn $200 cash back after you spend $1,500 on purchases in the first 6 months of account opening. This bonus offer will be fulfilled as 20,000 ThankYou® Points, which can be redeemed for $200 cash back.

on Wells Fargo's website

2% Earn unlimited 2% cash rewards on purchases

$200 Earn a $200 cash rewards bonus after spending $500 in purchases in the first 3 months.

1x-3x Earn unlimited 3X points on restaurants, travel, gas stations, transit, popular streaming services and phone plans. Plus earn 1X points on other purchases.

20,000 Earn 20,000 bonus points when you spend $1,000 in purchases in the first 3 months - that's a $200 cash redemption value.